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ABSTRACT 
Consumption of soy and soy products is associated with reduction in risk factors for 
heart disease, especially lowering plasma concentrations of lipoproteins and cholesterol. It is 
important to determine which soy protein-associated components including P-conglycinin, 
isoflavones, or group B soyasaponins, improve plasma lipid concentrations for decreasing 
cardiovascular disease risk. 
The effects on plasma lipid concentrations of p-conglycinin, one of the two major 
storage protein in soybeans, containing high and low levels of isoflavones (213 jimol v. 22 
Hmol/person/day) and soyasaponins (276 (imol v. 23 (xmol/person/day) and the mechanism 
of p-conglycinin to affect plasma lipid levels were investigated in mildly 
hypercholesterolemic women. A significant reduction of plasma total and LDL cholesterol 
occurred after 14 and 28 days during ingestion of P-conglycinin but only when it contained 
high levels of isoflavones and soyasaponins. A slight but nonsignificant increase in excretion 
of fecal bile acids and neutral sterols may have contributed to these changes. This study 
suggests that isoflavones and soyasaponins may be needed companions for P-conglycinin to 
exert a cholesterol lowering effect. 
The beneficial effects of daidzein, genistein, or glycitein (0.9 mmol/kg diet, purity > 
97%) on plasma lipid concentrations were investigated in female Golden Syrian hamsters fed 
these compounds for 4 weeks. Hamsters fed glycitein had significantly lower plasma total 
and non-HDL cholesterol levels by 15% and 24%, respectively, compared with those fed 
casein (P < 0.05). The percentage of urinary recovery of each isoflavone was glycitein > 
daidzein > genistein (32.2% > 4.6% > 2.2%, P < 0.05). These results suggest that glycitein's 
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greater cholesterol-lowering effect was due to greater bioavailability, as reflected in urinary 
recovery of glycitein compared with the other purified isoflavones. 
An animal study was conducted to determine if group B soyasaponins affect plasma 
lipid concentrations by increasing excretion of fecal bile acids and neutral sterols, to 
investigate the relationship between group B soyasaponin metabolite and plasma lipid 
concentrations, and to identify group B soyasaponin metabolites. Compared with hamsters 
fed casein, hamsters fed group B soyasaponins significantly lower plasma total cholesterol 
(by 20%), non-HDL cholesterol (by 33%), and triglycerides (by 18%). Cholesterol-lowering 
was probably by a mechanism involving greater excretion of fecal bile acids and neutral 
steroids (P < 0.05). Two fecal soyasaponin metabolite excretion phenotypes (high v. low) 
were observed. The high producers of soyasaponin metabolite showed significantly lower 
total/HDL cholesterol ratio compared with the low producers (1.38 ± 0.7 v. 1.59 + 0.13; P < 
0.03). Greater production of group B soyasaponin metabolite in hamsters was associated with 
improved plasma lipid profile. 
These findings suggest that both soy isoflavones and soyasaponins in nutritionally 
relevant concentrations contribute to the cholesterol-lowering effects of soy foods and soy 
protein ingredients, and might be useful as purified supplements for cholesterol-lowering as 
well. 
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GENERAL INTRODUCTION 
A. Introduction 
Atherosclerotic cardiovascular disease (CVD), principally coronary heart disease 
(CHD) and stroke, was the leading cause of death in the United States in 2001, accounting 
for more than 38% of all deaths (American Heart Association, 2004). Several clinical and 
experimental studies have shown the cardiovascular protective properties of soy components 
including soy protein itself, isoflavones, and soyasaponins (Anderson et al., 1995; Duranti et 
al., 2004; Song et al., 2003; Grouse et al., 1999; Fukui et al., 2002). 
It is well-known that a soy protein based diet improves plasma lipid status of humans 
and animals. A meta-analysis showed a significant relationship between soy consumption 
and decreased plasma total and LDL cholesterol and reduced risk of coronary heart disease 
(Anderson et al., 1995). P-conglycinin, one of the two major storage protein in soybeans, 
lowered plasma total cholesterol and triglyceride concentrations in rats compared with casein 
(Aoyama et al., 2001; Duranti et al., 2004). 
Considerable evidence suggests that alcohol-extractable components of soy protein 
are responsible for the hypocholesterolemic effects. Soy isoflavones are largely extracted 
from soy protein using alcohol. Isolated soy protein (25 g) with 62 mg isoflavones 
significantly reduced plasma total and LDL cholesterol concentrations in moderately 
hypercholesterolemic men and women (Crouse et al., 1999). Daidzein lowered plasma total 
and non-HDL cholesterol concentrations in hamsters compared with casein (Song et al., 
2003). Soyasaponins are another alcohol extractable component of soy protein and have been 
considered to have a role in the hypocholesterolemic effect of soy. Isoflavone-depleted soy 
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protein isolate, but containing 49% of soyasaponins, lowered plasma total cholesterol in rats 
(Fukui et al., 2002). A diet containing 1% soyasaponins decreased hepatic and plasma total 
cholesterol in rats (Oakenfull et al., 1984). 
Many previous studies used an isolated soy protein extract rich in isoflavones and 
soyasaponins (Clarkson et al., 2001; Song et al., 2003) or an alcohol-washed isolated soy 
protein deficient in isoflavones and soyasaponins (Song et al., 2003; Tovar-Palacio et al., 
1998) to investigate the cholesterol-lowering effects of isoflavones. Also, the contents of 
soyasaponins were not determined in these studies. Therefore, it is necessary to investigate 
which soy components are responsible for its cholesterol-lowering effects. 
B. Objectives of current research 
A great deal of attention has been focused on the health benefits of using soy and soy 
products for their hypocholesterolemic and anti-atherosclerotic effects. The overall objective 
of my doctoral research was to determine which components of soy, including soy protein 
itself isoflavones, or soyasaponins, improve plasma lipid concentrations, a key 
cardiovascular disease risk factor. Our central hypothesis states that the isoflavones and 
soyasaponins in association with P-conglycinin or isoflaovnes (daidzein, genistein, or 
glycitein) and soyasaponins, separate from P-conglycinin are responsible for the beneficial 
effects of soy on plasma lipid concentrations. 
To test the hypothesis, the proposed aims of my research were: 1. to examine the 
effect of P-conglycinin containing low or high levels of isoflavones and soyasaponins on 
plasma lipid concentrations and to investigate the mechanism of soy protein that affect 
plasma cholesterol concentrations by monitoring the excretion of fecal bile acids and neutral 
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sterols in mildly hypercholesterolemia women; 2. to determine if the cholesterol-lowering 
effects are due to daidzein, genistein, or glycitein by measuring plasma lipid concentrations 
in female Golden Syrian hamsters fed these compounds and the association between the 
urinary recovery of each isoflavone and plasma lipid levels; 3. to determine if group B 
soyasaponins lower plasma lipid levels by a mechanism involving greater excretion of fecal 
bile acids and neutral sterols in female hamsters, to investigate the relationship between 
group B soyasaponin metabolite and plasma lipid concentrations, and to identify group B 
soyasaponin metabolites. 
The information obtained in this study will help to clarify the bioactive components 
of soy protein responsible for the cholesterol-lowering effects and to understand the possible 
mechanisms of the hypocholesterolemic effects. 
C. Dissertation organization 
This dissertation consists of a literature review and three papers. The first paper, 
"Beta-conglycinin deficient in soy isoflavones and soyasaponins did not lower plasma 
concentrations of lipoproteins and cholesterol over time in mildly hypercholesterolemia 
women", will be submitted to the Journal of Nutrition. The second paper, "The isoflavone 
glycitein lowered plasma cholesterol in female Golden Syrian hamsters", will be submitted to 
Experimental Biology and Medicine. The third paper, "Group B soyasaponins lower plasma 
cholesterol and increase fecal bile acids in female Golden Syrian hamsters", will be 
submitted to Experimental Biology and Medicine. The papers are written in the format of the 
journals to which they will be submitted. A general conclusion is included following the 
three papers. 
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LITERATURE REVIEW 
A. Introduction to soy protein 
It has been suggested that consumption of soy and soy products is associated with 
certain health-promoting benefits, including hypocholesterolemic activity (Teixeira et al., 
2000; Bakhit et al., 1994), antitumor-promoting activity (Bennink et al., 2001; Wu et al., 
1998), and reducing postmenopausal bone loss (Ho et al , 1993; Horiuchi et al., 2000). 
Soybean, Glycine max (L.) Merr., is in the legume family and is rich in high quality 
protein. Soybeans contain 40% protein, 20% oil, 17% cellulose, 7% sugars, 6% ash, 5% 
crude fiber, and 5% miscellaneous. 
Soy protein is produced from whole ground soybeans by multiple processes that 
remove the oil and fiber to produce high protein powder. The two major storage proteins in 
soybeans are P-conglycinin and glycinin corresponding to 7S and 1 IS globulins, respectively 
(Koshiyama 1965; Thanh et al., 1975 and 1976; Derbyshire et al., 1976; Nagano et al., 1992; 
Shewry 1995; Shutov et al., 1996; Wu et al., 2000). The protein contents of P-conglycinin 
and glycinin fractions were about 98% and 92% on a purified dry basis, respectively (Wu et 
al., 2000). In addition to protein, P-conglycinin and glycinin fractions contain other naturally 
occurring soy components, such as isoflavones and soyasaponins that have biologically 
active properties. 
Soy protein is commonly consumed as a component of soy foods such as tofu, 
soymilk, soy nuts, soy yogurt, textured vegetable protein, vegetable-based soy burgers, miso, 
tempeh, and soy sauce. The estimated consumption of soy products in Asian countries is 
about 20 to 100 g/day (Wu et al., 1998; Nagata et al., 2003), compared with 3 to 10 g/day in 
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the United States (Kirk et al., 1999). 
B. Introduction to soy isoflavones 
Many studies have demonstrated the health protective properties of consuming soy 
isoflavones, including prevention of cancer (Lamartiniere et al., 1995; Pollard and Luckert, 
1997), reducing bone loss (Ho et al., 2001; Alekel et al., 2000), and lowering plasma 
cholesterol concentrations (Crouse et al., 1999; Merz-Demlow et al., 2000; Wangen et al., 
2001). 
Soy isoflavones are diphenolic phytoestrogens found in soybeans and soy-derived 
foods. The basic structure of isoflavones is two aromatic rings (A and B ring) linked by a 
three carbon aliphatic chain to form a pyran ring (C ring) (Figure 1). The B ring of isoflavone 
is joined at position 3 on the C ring. The soybean isoflavone aglucones include daidzein, 
genistein, and glycitein (Figure 1). Nine (3-glucoside forms are daidzin, genistin, glycitin, 6"-
O-acetyldaidzin, 6"-0-acetylgenistin, 6"-0-acetylglycitin, 6"-0-malonyldaidzin, 6"-0-
malonylgenistin, and 6"-0-malonylglycitin (Figure 2). Both acetylation and malonylation of 
isoflavone glucosides occurs at position 7 of the A ring. These glucoside conjugate forms of 
isoflavones are found primarily in soybeans. 
In the USDA-Iowa State University Isoflavone Database (1999), the isoflavone 
contents of soybeans are about 1 to 3 mg/g. Isolated soy protein contains isoflavones ranging 
from 0.5 to 2 mg/g depending on the processing method. Soy products such as tofu, soymilk, 
and miso provide about 0.2 to 0.5 mg of isoflavones/g fresh weight. Daily isoflavone intake 
in Asia varies among countries, ranging from 15 to 55 mg/day (Seow et al., 1998; Chen et al., 
1999; Wakai et al., 1999; Arai et al., 2000; Nagata et al., 2000; Kim and Kwon, 2001; 
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Figure 1. Chemical structure of soy isoflavone aglucone forms 
OH 
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Daidzin H H H 
6'-OMalonyl daidzin COCHzCOOH H H 
6'-0-Acetyl daidzin COCH3 H H 
Genistin H H OH 
6'-0-Malonyl genistin COCHzCOOH H OH 
6-O-Acetyl genistin COCH3 H OH 
Glycitin H OCH3 H 
6'-0-Malonyl glycitin COCH2COOH OCH3 H 
6-O-Acetyl glycitin COCH3 OCH3 H 
Figure 2. Chemical structures of isoflavone glucosidic forms 
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Somekawa et al., 2001). The estimated daily isoflavone intake was from 0.1 to 0.24 mg/d in 
postmenopausal women in the United States (de Kleijn et al., 2001). 
B.l Analysis of isoflavones in biological fluids 
Since dietary soy isoflavones have several health-promoting effects, analysis of the 
isoflavone content in human bodily fluids may be helpful to determine the role of soy 
isoflavones in preventing chronic disease. Interest in analytical methods, including 
chromatographic assay and immunoassay, for analysis of isoflavones has risen dramatically 
and been reviewed recently (Hendrich, 2002; Wang et al., 2002). Improved methods of 
detection of the isoflavones and isoflavone metabolites in biological fluids and tissues are 
important because isoflavone metabolism and bioavailability are key to understanding and 
assessing the potential health effects of isoflavones. 
Gas chromatography-mass spectrometry (GC-MS) method is particularly useful for 
the low concentrations of isoflavones and isoflavone metabolites in blood, feces, and urine. 
However, it is a very labor-intensive method even though this method offers very high 
chromatographic resolution. In 1984, the contents of isoflavones and their metabolites in 
human urine were first quantified by using gas chromatography (Axelson et al., 1984; 
Bannwart et al., 1984). Adlercreutz et al. (1991) developed a method to determine 
isoflavonoids and ligans and identify genistein in human urine by GC-MS using 14C-estrone 
as the internal standard. 
High performance liquid chromatography (HPLC) also allows the identification, 
confirmation, and quantitation of the physical properties of each isoflavone and its 
metabolite. The reverse-phase HPLC-ultraviolet absorbance (UV) detection method was 
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developed by Lundh et al. (1988) to detect isoflavone aglucons in bovine urine. Xu et ai. 
(1994) applied a method of Lundh et al. (1988) to human feces, plasma, and urine. Franke 
and colleagues (1995 and 1998) also used reverse-phase HPLC method to analyze isoflavone 
metabolites, equol and O-desmethylangolensin, in human fluids. Fluorescence detection is 
more sensitive and specific than UV absorption. Electrochemical detection is a useful method 
for determining phytoestrogens that contain electroactive compounds, such as phenolic 
groups. Electrochemical detection is more sensitive than UV detection for HPLC system. 
Gamache et al. (1998) analyzed phytoestrogens in plasma, urine, and tissue samples by using 
a HPLC system with eight electrochemical detection channels. 
Immunoassay methods, including radioimmunoassay (RIA), enzyme-linked 
immunosorbent assay (ELISA), and time-resolved fluoroimmunoassay (TR-FIA), are non-
chromatographic methods and provide a high degree of specificity and rapid screening of 
large numbers of samples. A RIA method has high sensitivity but involves radiation and a 
cross-reaction with structurally related compounds (Lapcik et al., 1997 and 1998). An ELISA 
method is a non-isotopic immunoassay but the sensitivity of this method is about 100 times 
less than the RIA method. TR-FIA has been suggested as a powerful method for analysis of 
isoflavones in plasma and urine samples (Adlercreutz et al., 1998; Uehara et al., 2000; 
Stumpf et al., 2000). The advantages of this method are lack of radiation and reagent stability 
in comparison with RIA, and high sensitivity over ELISA. 
In terms of expense, equipment, supplies, and labor, the HPLC-UV detection or 
HPLC with electrochemical detection method seems to be adequate for analysis of 
isoflavones and their metabolites. 
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B.2 Metabolism and bioavailability of isoflavones 
The predominant isoflavones in soy products are mostly the glucoside forms of 
daidzein, genistein, and glycitein (Wang and Murphy, 1994; Murphy and Hendrich, 2002). 
The glucoside forms may undergo chemical hydrolysis by gastric acid or enzymatic 
hydrolysis by mammalian intestinal microorganisms, resulting in the removal of the sugar 
moiety to yield aglucones. Following absorption of these aglucones from intestinal lumen, 
these compounds are readily metabolized to glucuronide and sulfate conjugates in the 
intestinal mucosa and liver (Sfakianos et al., 1997; Barnes et al., 1998; Coldham et al., 1999). 
A large portion of these conjugates is excreted in bile. Then, these conjugates are reconverted 
to aglucone forms and are reabsorbed and further degraded to different metabolites by gut 
microorganisms or excreted in the urine. Equol and O-desmethylangolensin (ODMA) via 
their respective intermediates, dehydroequol and dihydrodaidzein, respectively, and cis-4-
equol have been identified as the major metabolites of daidzein (Kelly et al., 1993; Heinonen 
et al., 1999; Bayer et al , 2001). Genistein can be metabolized to 6'-hydroxy-0-
desmethylangolensin via the intermediate dihydrogenistein (Joannou et al., 1995) andp-
ethylphenol (Barnes et al., 1998; Goldwyn et al., 2000). Gut microbial metabolites of 
glycitein have been tentatively identified in human urine as 5'-C)H-0-desmethylangolensin 
and 5'-methoxy-0-desmethylangolensin (Heinonen et al., 2000). Investigation of metabolic 
pathways and metabolites of soy isoflavones may be helpful to understand the potential 
health protective properties of isoflavones. The gut microorganisms that are involved in 
metabolic pathways and the biological activities of these metabolites should be further 
investigated. 
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Bioavailability refers to the proportion of a certain substance absorbed and reaching 
the target tissues. The bioavailability of soy isoflavones is influenced by many factors, 
including endogenous digestive and biotransformation enzymes and activities of gut 
microflora. Thus, understanding the bioavailability of isoflavones is important to assess the 
potential health effects of isoflavones. Different chemical structure of isoflavones may affect 
the metabolic fate and bioavailability. Setchell et al. (2002) investigated the intestinal 
absorption of isoflavone glucosides in healthy premenopausal women who ingested either 50 
mg of daidzin or genistin or 250 mL soymilk. Only aglucone forms, daidzein or genistein, 
were detected in plasma. The results suggested that hydrolysis of the sugar moiety was 
necessary for the absorption of isoflavone glucosides and increased bioavailability of soy 
isoflavones. Setchell et al. (2001) found that the total amount of isoflavones in the plasma 
over time (AUG, area under curve) was not different between isoflavone aglucone and 
glucosides forms, suggesting that isoflavone glucosides just needed more time to reach the 
maximum plasma isoflavone concentrations than aglucone forms because of hydrolysis of 
the sugar. 
The metabolic response to the ingested isoflavones varies in human subjects eating 
soy products (Franke et al., 1994; Xu et al., 1994 and 1995; Kelly et al., 1995; King and 
Bursill 1998; Watanabe et al., 1998; Zhang et al., 1999). Xu et al. (1994) investigated the 
bioavailability of daidzein and genistein in human subjects consuming soymilk. The fecal 
recovery of isoflavones was only 1 to 2% of the ingested dose. The average 24 h urinary 
recoveries of daidzein and genistein were approximately 21% and 9%, respectively. The data 
indicated that daidzein is more bioavailable than genistein, as reflected in urinary recovery of 
daidzein compared with that of genistein. Zhang et al. (1999) investigated the bioavailability 
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of glycitein in comparison with daidzein and genistein. Seven females and seven males 
consumed approximately 71 mg and 72 mg total aglucone isoflavones/day (approximately 
0.56 mmol and 0.57 mmol/kg diet) from soymilk and soy germ. The average 48 h urinary 
recoveries of daidzein, glycitein, and genistein were approximately 52%, 47%, and 37%, 
respectively, suggesting that bioavailability is daidzein = glycitein > genistein. The different 
recoveries of each isoflavone in feces or urine may be explained by the extensive metabolism 
or degradation of isoflavones by intestinal microorganisms. 
Single-dose studies have been conducted to investigate the plasma and urinary 
kinetics of daidzein and genistein in human (Watanabe et al., 1998; King and Bursill, 1998). 
Watanabe et al. (1998) reported that isoflavone concentrations in plasma reached maximum 
values of 1.56 pmol/L at 6 h for daidzein and 2.44 p.mol/L at 6 h for genistein. The rate of 
urinary excretion of daidzein was greater than that of genistein following intake of 60 g of 
kinako (baked soy powder; approximately 56 mg total aglucone isoflavones/d), with mean 
recoveries of 36% and 18% for daidzein and genistein, respectively. King and Bursill (1998) 
found that concentrations of plasma daidzein and genistein rose slowly and reached 
maximum values of 3.14 pmol/L at 7.4 h and 4.09 pmol/L at 8.4 h, respectively. The greater 
proportion of the ingested isoflavones excreted as daidzein (62%) than genistein (22%) 
throughout the postmeal period. However, King and Bursill concluded that the bioavailability 
of daidzein and genistein are similar because the ratio of the areas under the plasma content 
versus time curves for daidzein and genistein was equal to the ratio of the concentrations of 
the respective isoflavones in the soybean flour-based meal. 
Xu et al. (1995) investigated fecal isoflavone disappearance. Intestinal half-lives of 
daidzein and genistein were estimated at 7.5 and 3.3 h, respectively, suggesting that more 
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rapid disappearance of genistein may be due to lower apparent absorption of genistein 
compared with that of daidzein. Zheng et al. (2003) reported that women who showed low 
fecal genistein disappearance rate and rapid gut transit time had greater genistein 
bioavailability, as reflected in urinary recovery of genistein compared with women who had 
high genistein disappearance rate and long gut transit time. Hendrich et al. (1998) showed 
three different isoflavone disappearance phenotypes in humans and a negative correlation 
between plasma isoflavone concentrations and isoflavone disappearance rate constant in 
young adult men. These findings suggested that individual variability in metabolic response 
to isoflavones may be due to differences in the relative ability of gut microorganism to 
degrade isoflavones. 
B.3 Toxicity of isoflavones 
The potential toxicity of soy isoflavones must be considered and addressed. A variety 
of feeding or intervention studies have indicated that oral exposure to soy isoflavones does 
not produce toxic effects (Anastasia et al., 1990; National Cancer Institute, 1996; Murrill et 
al., 1996; Rao et al, 1997; Flynn et al., 2000; Arjmandi et al., 1998a and 1998b; Lamartiniere 
et al., 1998; Casanova et al., 1999; Picherit et al., 2000; You et al., 2002). However, fewer 
studies have reported the subchronic and chronic toxicities of soy isoflavones. Whereas soy 
protein isolate with isoflavones (approximately 1.6 mmol/kg diet)(Aijmandi et al., 1998a and 
1998b) or genistein alone (500 gg/g body weight)(Murrill et al., 1996) are not uterotropic, 
subcutaneous administration of genistein (150-500 mg/kg body weight/d) showed short-term 
uterotrophic effects in rats and mice (Brown and Lamartiniere, 2000; Ishimi et al., 2000). 
Song et al. (1999) reported that female B6D2F1 mice dosed with glycitein (3 mg/day) by 
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gavage for 4 days showed a uterophic effect. Consumption of 60 g soy containing 45 mg 
isoflavones for 2 weeks in women with benign and malignant breast disease stimulated breast 
tissue proliferation (McMichael-Phillips et al., 1998). However, isoflavone-rich soy protein 
isolate did not induce proliferation in endometrial and mammary tissue in surgically 
postmenopausal female macaques (Foth and Cline, 1998). Existing observational and 
epidemiologic studies support the safety of isoflavones as typically consumed in diets based 
on soy or soy containing products. However, more research on the safety of soy isoflavone 
intake should be done. 
C. Introduction to soyasaponins 
Saponins are widely distributed and have been identified more than a thousand 
different types in a variety of plants (Hostettmann and Marston, 1995). Legumes are rich 
sources of dietary saponins. 
Soyasaponins are the triterpenoid glycosides naturally occurring in a variety of 
leguminous plants such as soybeans, alfalfa, cowpeas, lentils, runner beans, and kidney beans 
(Price et al., 1986; Tsukamoto et al., 1995; Ruiz et al., 1996; Kinjo et al., 1998; Oleszek et 
al., 1998). Soyasaponins have been reported to possess the health benefits including 
hypocholesterolemic (Oakenfull et al., 1984; Sidhu and Oakenfull, 1986), anticarcinogenic 
(Rowlands et al., 2002; Gurfinkel and Rao, 2003), and antimutagenic (Berhow et al., 2000) 
activities. Soybean saponins are classified into group A and B on the basis of their aglycone 
parts, soyasapogenol A and soyasapogenol B, respectively (Figure 3). The primary saponins 
in soybeans are the bisdesmosidic group A soyasaponins with two different polysaccharides 
and the monodesmosidic group B soyasaponins with one di- or tri-saccharide chain. Ireland 
15 
et al. (1986) and Gu et al. (2002) reported that whole soybean seeds contain about 25 to 40% 
group A soyasaponins and 60 to 75% group B soyasaponins. Shiraiwa et al. (1991) identified 
eight different group A soyasaponins, Aa, Ab, Ac, Ad, Ae, Af, Ag, and Ah (Figure 4). Group 
B soyasaponins are the predominant saponins in soybean and have a 2,3-dihydro-2,5-
dihydroxy-6-methyl-4H-pyran-4-one (DDMP) group conjugated to the C-22 position of 
soyasapogenol B. Kudou et al. (1993) isolated five isomers of group B soyasaponins, named 
soyasaponin Pg, Pa, yg, y a, and ag, from soybeans (Figure 5). DDMP-conjugated 
soyasaponins were easily converted to non-DDMP soyasaponins, named soyasaponin I, H, 
III, IV, and V, respectively (Daveby et al., 1998; Yoshiki et al., 1998; Gu et al., 2002). 
Hu et al. (2002) reported that DDMP-conjugated group B soyasaponins were detected 
in the raw soybean flour (-3 .3 pmol/g), whereas non-DDMP soyasaponins were detected in 
the processed soy products and ingredients (about 0.2 to 114 pmol/g). Murphy's group (Hu et 
al., 2002) reported that the soyasaponin contents, specifically soyasaponin ag, Pg, Pg, 
Figure 3. Chemical structures of soyasaponin precursors soyasapogenol A and B 
H 
OH 
soyasapogenol A soyasapogenol B 
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H3C. a\\CH3 
COOH 
CHoOH 
\ 
OAc 
R1 R2 R3 
Soyasaponin Aa CH2OH p-D-Glc H 
Soyasaponin Ab CH2OH P-D-GIc CH2OAC 
Soyasaponin Ac CH2OH a-L-Rha CH2OAc 
Soyasaponin Ad H P-D-Glc CH2OAc 
Soyasaponin Ae CH2OH H H 
Soyasaponin Af CH2OH H CH2OAc 
Soyasaponin Ag H H H 
Soyasaponin Ah H H CH2OAc 
Figure 4. Chemical structures of group A soyasaponins (Yoshiki et aL 1998) 
Glc: glucopyranosyl; Rha: rhamnopyranosyl; Ac: acetyl 
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>cli 
DDMP 
COOH 
9 HP CBjCH 
R2 R1 R2 DDMP 
Soyasaponin Pg CH2OH a-L-Rha Y 
Soyasaponin I CH2OH a-L-Rha N 
Soyasaponin pa H a-L-Rha Y 
Soyasaponin II H a-L-Rha N 
Soyasaponin yg CH2OH H Y 
Soyasaponin III CH2OH H N 
Soyasaponin Pa H H Y 
Soyasaponin IV H H N 
Soyasaponin ag CH2OH P-D-Glc Y 
Soyasaponin V CH2OH P-D-Glc N 
Figure 5. Chemical structures of group B soyasaponins (Kudou et aL 1994) 
Rha: rhamnopyranosyl; Glc: glucopyranosyl; 
DDMP: 2,3-dihydro-2,5-dihydroxy-6-methyl-4H-pyran-4-0/ie 
Y: yes; N: no. 
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soyasaponin V, I, and II, of soy products such as commercial soy burgers and meatless franks 
are about 0.5 to 1.8 nmol/g and 0.02 to 0.3 pmol/g, respectively. 
C.l Analysis of soyasaponins 
Analytical methods have been developed for the separation, identification, and 
quantification of soyasaponins from soybean and soy products, including HPLC with UV 
(Ireland et al., 1986; Shiraiwa et al., 1991; Kudou et al., 1993; Hu et al., 2002) or evaporative 
light scattering detector (ELSD) (Rupasinghe et al., 2003), liquid chromatography (LC) 
combined with thermospray mass spectrometry (Fuzzati et al., 1997) or electrospray 
ionization mass spectrometry (Gu et al., 2002; Berhow et al., 2002; Dalluge et al., 2003). 
A method for detection of the soyasaponins and their metabolites in biological fluids 
was developed by Hu et al. (2004a), based on HPLC combined with UV detection. Hu et al. 
(2004a) found two metabolites of soyasaponin I, soyasapogenol B and soyasapognin III, in 
vitro fermentation system (Figure 6). In an in vivo study, only soyasapogenol B was detected 
in human feces but no soyasaponins or their metabolites were detected in 24-h urine 
samples. To determine and assess the potential health effects of soyasaponins, improved 
methods for detection of the soyasaponins and their metabolites in biological fluids must be 
developed. 
C.2 Metabolism and bioavailability of soyasaponins 
Not many of the biological activities associated with soyasaponins have been 
investigated because of the lack of availability of large quantities of purified soyasaponins 
and efficient methods for the detection and identification of soyasaponins and their 
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Figure 6. Structures of soyasaponin I and its metabolites, soyasaponin HI and 
soyasapgenol B (Hu et al. 2003) 
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metabolites. 
It has been considered that soyasaponins are poorly absorbed in the digestive tract. 
Thus, soyasaponins may be either excreted unchanged or metabolized in the gut. In in vivo 
experiments, soyasaponins or soyasapogenols (aglycone forms) were not detected in the 
blood of rats, mice, or chicks (Gestetner et al., 1968), suggesting that ingested soybean 
saponins may not be absorbed into the blood stream as soyasaponins or soyasapogenols. Hu 
et al. (2004b) reported that soyasapogenol B but no group B soyasaponins was detected in 
human feces after a single dose of soy extract containing 434 [imol of group B soyasaponins. 
Neither soyasapogenol B nor soyasaponin metabolites were found in a 24 h urine samples. 
Using an in vitro system, both soyasaponins and soyasapogenols were identified when 
the contents of the cecum and colon were incubated with soybean saponin extract for 3 hours 
at 37°C (Gestetner et al., 1968). The sugars, glucose, arabinose, galactose, rhamnose, and 
glucuronic acid, liberated by the soybean saponins-hydrolzing enzymes (nonspecific 
glycosidases) purified from the cecal microorganisms of rats. Gurfmkel and Rao (2003) 
reported that colonic microflora readily hydrolyzed the group A and group B soyasaponins to 
soyasapogenol A and soyasapogenol B in vitro. Hu et al. (in press, b) found that two gut 
microbial metabolites of soyasaponin I, soyasaponin III, and soyasapogenol B, were detected 
using an in vitro fermentation system. These results suggest that soybean saponins were 
hydrolyzed to soyasapogenols, partially hydrolyzed forms, and sugars by mammalian gut 
microbial enzymes. Rowland et al. (1970) and Hawksworth et al. (1971) found that human 
intestinal bacteria have glycosidase and ^-glucuronidase activities and may hydrolyze 
soybean saponins to yield aglycones or partially hydrolyzed forms in the human intestinal 
tract. It was confirmed by Hu et al. (2004a) that only soyasapogenol B (8.4% fecal recovery 
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of ingested dose of group B soyasaponins) was detected in human feces. More detailed 
information under in vivo conditions is needed to elucidate and understand the fate of 
soybean saponins in animals and humans. 
C.3 Toxicity of soyasaponins 
A dose of up to 0.5 mg soyasaponin I/plate in the Ames mutagenicity assay was 
reported not to produce mutagenic effects (Czeczot et al., 1994). After cultured rat 
hepatocytes were exposed to CCU for 1 hour, soyasaponin I showed antihepatotoxic activity 
to inhibit the elevation of glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic 
transaminase (GOT) activities, except at the highest dose (Miyao et al., 1998). Hu et al. 
(2004a) investigated the cytotoxicity of soyasaponin I and soyasapogenol B by measuring 
cell viability in a human colon cancer CaCo2 cell. Compared with control, soyasaponin I did 
not show an apparent toxic effect at concentrations up to 3 mM, while soyasapogenol B at 1 
mM or higher concentrations significantly decreased cell viability. Several in vitro studies 
showed the interaction between soyasaponins and nutrients. Crude soybean soyasaponins 
increased resistance of bovine serum albumin (BSA) to chymotrypsin hydrolysis (Ikedo et 
al., 1996), suppressed chymotrypsin hydrolysis of soy proteins (Shimoyamada et al., 1998), 
and protease hydrolysis of (3-lactoglobulins. Another nutritional problem of dietary saponins 
is that of decreasing mineral absorption. Southon et al. (1988a and b) reported that rats fed a 
diet with 2% of gypsophila saponins or alfalfa saponins showed greater fecal excretion of 
minerals, while a diet containing a similar level of soyasaponin I did not affect zinc (Zn) and 
iron (Fe) absorption. More studies are needed to investigate the safety of soyasaponins. 
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D. Introduction to atherosclerotic cardiovascular disease 
Atherosclerotic cardiovascular disease (CVD), principally coronary heart disease 
(CHD) and stroke, was the leading cause of death in the United States in 2001, accounting 
for more than 38% of all deaths (1 in every 2.6 deaths) (AHA 2004). Coronary heart disease 
and stroke caused nearly 669,000 and 282,000, respectively. In 2004, the direct and indirect 
cost of heart disease and stroke is about $133.2 billion and $53.6 billion, respectively (AHA 
2004). 
Atherosclerosis is a process of thickening and hardening of the arteries and causes 
nearly three-fourths of all deaths from CVD. Elevated blood cholesterol, specifically those of 
total and low-density lipoprotein (LDL) cholesterol, or decreased high-density lipoprotein 
(HDL) cholesterol concentrations, are associated with the development of atherosclerotic 
CVD. 
E. Link between soy components and atherosclerotic cardiovascular disease 
Great interest has focused on the cardiovascular protective properties of soy 
components including soy protein itself, isoflavones, and soyasaponins. Huff et al. (1977) 
investigated the effects of intact soybean protein or a mixture of amino acids that was 
identical to the composition of intact soybean protein in lowering plasma cholesterol 
concentrations. Rabbits fed diets containing a mixture of amino acids did not show as much 
decrease in plasma cholesterol as those fed the intact protein. The data suggested that some 
components in intact soybean protein other than the amino acids may play a role in plasma 
lipid metabolism. 
Soy protein-associated components including (3-conglycinin and glycinin 
corresponding to 7S and 1 IS globulin, respectively, were investigated for their effects on 
plasma lipid metabolism (Wright, 1985 and 1988, Lovati et al., 1992, 1998 and 2000; 
Manzoni et al., 2003; Duranti et al., 2004). Peptides from (3-conglycinin increased LDL 
receptor expression in human hepatoma (HepG2) cells while glycinin peptides had no effect 
(Lovati et al., 1992). Lovati et al. (1998) reported that the soybean 7S globulin (p-
conglycinin), particularly the a + a' subunits, upregulated hepatic LDL receptors in HepG2 
cells. Duranti et al. (2004) found that purified a' subunit from soybean 7S globulin 
significantly decreased plasma total cholesterol and triglycerides and increased hepatic 0-
VLDL receptor expression in rats. These data imply that (3-conglycinin may lower plasma 
cholesterol concentrations, specifically LDL cholesterol, through increased hepatic LDL 
receptor expression. 
Several human and animal studies indicate that alcohol-extractable components of 
soybean protein are responsible for the hypocholesterolemic and anti-atherogenic effects 
(Song et al., 2003; Demonty et al., 2002; Blair et al., 2002; Adams et al., 2002; Clarkson et 
al., 2001; Gardner et al., 2001; Uesugi et al., 2001; Crouse et al., 1999; Peluso et al., 2000; 
Balmir et al., 1996; Anthony et al., 1996 and 1997, Tovar-Palacio et al., 1998; Wangen et al. 
2001; Merz-Demlow et al., 2000) Isoflavones are largely extracted with alcohol from 
soybean protein. Accumulating evidence indicates that isoflavones reduce CVD risk factors. 
Soybean saponins are one of major alcohol-extractable components of soybean protein that 
may affect plasma cholesterol concentrations (Sidhu and Oakenfull, 1986; Oakenfull et al., 
1984; Oakenfull and Sidhu, 1990; Potter e al., 1995; Ueda et al., 1996; Fukui et al., 2002). 
Purified saponins from soybean, soapwort, and quillaja added to the diet (10% by weight of 
diet) reduced plasma cholesterol in rats by increasing excretion of bile acids or decreasing 
cholesterol absorption from the small intestine (Sidhu and Oakenfull, 1986). Fukui et al. 
(2002) reported that Sprague-Dawley rats fed soy protein isolate, either intact or depleted of 
isoflavones but containing 49% of soyasaponins in a soy protein isolate-based diet, had 
significantly lower plasma total cholesterol concentration compared with those fed casein. 
F. Effects of soy components on plasma lipids and lipoproteins 
Many studies have focused on the health benefits of using soybean and soy products 
for hypocholesterolemic activity. Total plasma cholesterol above 240 mg/dl, LDL cholesterol 
above 160 mg/dl, and HDL cholesterol below 40 mg/dl are strong indicators of CVD risk. 
Every 1% drop in plasma total cholesterol may be associated with a 2% reduction in 
coronary heart disease incidence (Roussouw and Rifkind, 1990). Therefore, optimal 
concentrations of plasma lipid and lipoproteins are important in the prevention of 
atherosclerotic CVD. 
F. 1 Hypocholesterolemic effect of soy protein 
It is well-known that a soy protein diet improves the blood lipid profiles of humans 
and animals (Potter et al., 1993; Bakhit et al., 1994; Anderson et al., 1995; Teixeira et al., 
2000; Aoyama et al., 2001; Moriyama et al., 2004). A meta-analysis showed a significant 
relationship between soy consumption and decreased total and LDL cholesterol by 9% and 
13%, respectively, and lesser risk of heart disease (Anderson et al., 1995). In 1999, the U S 
Food and Drug Administration (FDA) approved a health claim that "diets low in saturated fat 
and cholesterol that include 25 g of soy protein a day may reduce the risk of heart disease." 
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Consumption of 25 g soy protein per day significantly decreased plasma total cholesterol by 
7-8% in men with initial total cholesterol concentration > 5.7 mmol/L compared with the 
casein diets (Bakhit et al., 1994). Furthermore, Teixeira et al. (2000) investigated the 
minimum amount of soy protein needed to lower plasma lipid concentrations in 81 men (23-
74 year of age) with moderate hypercholesterolemia. Compared with casein, consuming as 
little as 20 g of isolated soy protein significantly reduced plasma total cholesterol, non-HDL 
cholesterol, and apolipoprotein B concentrations by week 6. Aoyama et al. (2001) reported 
that a 20% P-conglycinin diet significantly lowered plasma total cholesterol and triglyceride 
concentrations in male Wistar young and adult rats compared with a 20% casein diet. Male 
mice fed soybean P-conglycinin for 2 weeks had significantly lower plasma triglyceride 
concentration compared with those fed casein. The triglyceride-lowering effect of |3-
conglycinin was mediated by an increase of p-oxidation, suppression of fatty acid synthase, 
or an increase of fecal triglyceride excretion (Moriyama et al., 2004). 
In addition, the cholesterol-lowering effect of the alcohol-washed isolated soy protein 
has been reported (Balmir et al., 1996; Blair et al., 2002; Song et al., 2003). In the study by 
Balmir et al. (1996), ethanol-acetone extracted isolated soy protein significantly reduced 
plasma total and non-HDL cholesterol concentrations in Sprague-Dawley rats compared with 
casein. In male hamsters, isolated soy protein with isoflavones removed lowered the plasma 
LDL+VLDL cholesterol concentration compared with casein (Blair et al., 2002). Compared 
with casein, isolated soy protein lacking isoflavones significantly decreased plasma total and 
non-HDL cholesterol concentrations in male and female Golden Syrian hamsters (Song et al., 
2003). These results indicate that soy protein itself does play a role in the 
hypocholesterolemic activity. 
In view of the growing attention to the mechanisms of the hypocholesterolemic 
response to soy protein, it was of interest to examine specific soy protein and its related 
components for their ability to lower plasma lipid concentrations. The 7S globulin and in 
particular the a + a' subunit s up-regulated hepatic LDL receptors in HepG2 cells (Lovati et 
al., 1998). Manzoni et al. (2003) also showed that the LDL receptor upregulation in HepG2 
cells was induced by the a' subunit of 7S globulin. Purified a' subunit from soybean 7S 
globulin significantly reduced plasma total cholesterol and triglycerides and upregulated 
hepatic P-VLDL receptor in rats (Duranti et al., 2004). These data suggest that soy protein 
may affect plasma concentrations of lipoproteins and cholesterol through LDL receptor-
dependent pathways. Some investigators have reported that dietary soy protein increased 
excretion of fecal bile acids and neutral steroids (Beynen, 1990; Schwerin et al., 2002; 
Wright and Salter 1998; Nagaoka et al., 1999). Wright and Salter (1998) showed that fecal 
bile acids were 2-fold greater in soy protein-fed hamsters than in hamsters fed a casein diet. 
There was a significant correlation between soy intake and bile acid excretion. Hepatic 
cholesterol decreased by 32%, as the amount of soy protein consumed increased from 16.3% 
to 36.3% soy, suggesting that it is this pool of cholesterol that is used to replace the excreted 
bile acids. 
F. 2 Hypocholesterolemic effect of soy isoflavones 
Several animal studies showed that intact soy protein has favorable effects on plasma 
lipid and lipoprotein concentrations compared with alcohol-washed soy protein (Anthony et 
al., 1996 and 1997; Kirk et al., 1998; Ni et al., 1999; Clarkson et al., 2001). Anthony et al. 
(1997) found that male Cynomolgus monkeys fed intact isolated soy protein (1.2 mmol total 
isoflavones/kg diet) for 14 months had significantly lower plasma total and LDL+VLDL 
cholesterol levels compared with both casein group and isolated soy protein with the 
phytoestrogen mostly extracted (0.13 mmol total isoflavones/kg diet). Plasma and liver total 
cholesterol were significantly lower in ExHC rats fed intact isolated soy protein (providing 
approximately 1.1 mmol total isoflavones/kg diet) than in those fed ethanol-extracted isolated 
soy protein (Ni et al., 1999). Clarkson et al. (2001) also reported that both soy protein isolate 
containing soy phytoestrogens (1.0 mmol total isoflavones/kg diet) and soy phytoestrogens-
depleted soy protein isolate with conjugated equine estrogens significantly lowered plasma 
total and LDL+VLDL cholesterol concentrations in ovariectomized female Cynomolgus 
monkeys compared with soy protein isolate depleted soy phytoestrogens (0.005 mmol total 
isoflavones/kg diet) Song et al. (2003) found that soygerm extract or daidzein (1.3 mmol 
total isoflavones/kg diet) significantly decreased plasma total and non-HDL cholesterol 
levels compared with casein. These findings suggest that an isolated soy protein extract rich 
in isoflavones or consumption of a high level of isoflavones lowered plasma total and non-
HDL cholesterol concentrations. 
The relationship between the amount of isoflavones in the diet and the effect on the 
plasma lipid profiles was investigated in animal models (Balmir et al., 1996; Tovar-Palacio et 
al., 1998). Balmir et al. (1996) investigated the effects of an alcohol extract of isolated soy 
protein, which contains isoflavones, on plasma cholesterol concentrations. A significant 
reduction in plasma LDL cholesterol concentration was observed in male Golden Syrian 
hamsters fed diets containing intact isolated soy protein (ISP), ISP with added ethanol extract 
(providing 0.6 mmol total isoflavones/kg diet; ISP+), casein with ethanol extract (providing 
0.3 mmol total isoflavones/kg diet; casein+) for 8 weeks compared with those fed casein. 
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Addition of twice the level of extract to casein (providing 0.6 mmol total isoflavones/kg diet; 
casein++) resulted in a slight but nonsignificant reduction in plasma total and non-HDL 
cholesterol concentrations compared with casein. Gerbils fed alcohol-washed isolated soy 
protein (containing approximately 0.04 mmol/kg diet; ISP) or supplemented with one of 
three different levels of an alcohol extract of isolated soy protein to ISP (providing 
approximately 1.5 mmol, 2.6 mmol, or 4.4 mmol total isoflavones/kg diet) had significantly 
lower plasma total cholesterol, LDL+VLDL cholesterol, and apolipoprotein B concentrations 
than those fed casein. The addition of isoflavone-containing extract to ISP did not further 
lower plasma cholesterol levels (Tovar-Palacio et al., 1998). These results suggested the 
existence of a threshold above which an increase in isoflavone intake had no additional 
cholesterol-lowering effect 
Several human studies also reported that increasing the level of isoflavones in the diet 
are more effective in improving plasma lipid and lipoprotein concentrations (Grouse et al., 
1999; Merz-Demlow et al., 2000; Wangen et al., 2001; Gardner et al., 2001). Grouse et al. 
(1999) investigated the effects of feeding 25 g isolated soy protein containing different 
amounts of isoflavones for 9 weeks in moderately hypercholesterolemic men and women. 
Consumption of 25 g isolated soy protein with 62 mg of isoflavones (approximately 0.5 
mmol/kg diet) significantly reduced plasma total and LDL cholesterol by 4% and 6%, 
respectively, compared with casein. Plasma LDL cholesterol was significantly decreased in 
premenopausal women consuming 53 g soy protein isolate with 129 mg isoflavones 
(approximately 1.0 mmol/kg diet) compared with women consuming soy protein isolate with 
10 mg isoflavones (approximately 0.08 mmol/kg diet) (Merz-Demlow et al., 2000). In the 
study by Wangen et al. (2001), postmenopausal women consuming 63 g of isolated soy 
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protein containing 132 mg isoflavones (approximately 1.04 mmol/kg diet) had significantly 
lower plasma LDL cholesterol compared with subjects consuming isolated soy protein with 7 
mg isoflavones (approximately 0.06 mmol/kg diet). 
Recent studies investigated the effect of adding pure synthetic isoflavones or isolated 
pure isoflavones from soybean fraction to the casein diet to avoid the confounding effects of 
other components present in alcohol extract from soy protein (Nogowsky et al., 1998; Uesugi 
et al., 2001; Demonty et al., 2002; Song et al., 2003). Uesugi et al. (2001) showed that 
ovariectomized rats fed isolated pure isoflavone glycosides daidzin (25 or 50 mg/kg body 
weight/d) or genistin (50 mg/kg body weight/d) orally using a stomach tube for 4 weeks had 
significantly lower plasma total cholesterol and triglyceride concentrations compared with 
those fed casein. Compared with Sprague-Dawley rats fed casein, rats fed diets containing 
either intact soy protein isolate (containing 1.6 mmol/kg diet) or casein plus synthetic 
isoflavones (providing approximately 1.4 mmol/kg diet) had significantly reduced plasma 
triglycerides (Demonty et al., 2002). Song et al. (2003) reported that plasma total and non-
HDL cholesterol concentrations were significantly lowered by 22-24% and 30-38%, 
respectively, in hamsters fed casein plus pure synthetic daidzein (1.3 mmol/kg diet; purity 
>98%) compared with those fed casein. Theses studies suggest that soy isoflavones are 
responsible, at least in part, for lowering plasma cholesterol concentrations, separate from 
soy protein. 
Potential mechanisms of soy isoflavones in lowering plasma cholesterol 
concentrations are not clear. Soy isoflavones have similar structure to natural estrogens and 
can bind estrogen receptors (ER-a and -(3), especially ER-|3. The loss of estrogen increased 
plasma total cholesterol, LDL cholesterol, and triglycerides and decreased HDL cholesterol 
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concentration in women (Jensen, 1992; Gaspard et al., 1995). Jensen (1992) investigated the 
changes in plasma lipid concentrations after a natural menopause in 170 premenopausal 
women. After menopause, women significantly increased plasma total (by 6%) and LDL 
cholesterol (by 8%) and decreased HDL cholesterol (by 7%) concentration. It may be 
possible that soy isoflavones may affect plasma lipid concentrations through their estrogenic 
activity. Angel in et al. (1992) reported that hepatic 125I-LDL binding activity (reflecting the 
expression of the LDL receptor) was increased in the estrogen-treated men compared with 
control. Kirk et al. (1998) reported that soy protein isolate containing isoflavones at 1.33 
mmol/kg diet lowered plasma LDL cholesterol by 30% in C57BL/6 mice compared with soy 
protein lacking isoflavones. However, no cholesterol-lowering effect by soy protein was 
observed in LDL receptor-deficient mice. Based on the results from these studies, soy 
isoflavones may lower LDL cholesterol concentration through increased gene expression and 
hepatic LDL receptor activity, thereby increasing LDL clearance. 
F. 3 Hypocholesterolemic effect of soyasaponins 
It has been proposed that soyasaponins, one of the primary phytochemicals associated 
with soy protein, may play a role in the hypocholesterolemic effect of soy (Oakenfull et al, 
1984; Potter et al., 1995; Ueda et al., 1996; Fukui et al., 2002). Compared with Sprague-
Dawley rats fed casein, plasma total cholesterol concentration was significantly lowered in 
rats fed soy protein isolate, either intact or depleted of isoflavones but containing 49% of the 
amount of saponins present in the soy protein isolate-based diet (Fukui et al., 2002). Hepatic 
and plasma total cholesterol was significantly decreased in male Wistar rats fed a standard 
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diet that contained 1% cholesterol plus 1% purified soyasaponins compared with those fed a 
standard diet with 1% cholesterol (Oakenfull et al., 1984). 
The potential mechanisms responsible for the hypocholesterolemic effects of 
soyasaponins and synthetic saponins have been investigated (Oakenfull et al., 1984; Price et 
al., 1987; Oakenfull and Sidhu, 1990; Morehouse et al., 1999; Oakenfull, 2001). In the study 
by Morehouse et al. (1999), the intestinal absorption of cholesterol was significantly 
decreased in male New Zealand white rabbits fed synthetic saponins, pamaqueside and 
tiqueside, compared with those fed control. There was a significant relationship between 
decreased hepatic and plasma total and non-HDL cholesterol concentrations and increased 
fecal neutral sterol excretion. Oakenfull et al. (1984) found greater fecal excretion of bile 
acids and neutral sterols in rats fed a diet containing 1% cholesterol and 1% purified 
soyasaponins. A diet containing crude soyasaponins (10 g/kg diet) decreased the rate of 
absorption of bile salts by the formation of large mixed micelles with bile acids (Sidhu and 
Oakenfull, 1986). Two mechanisms of soyasaponins in lowering plasma lipid concentrations 
were proposed by Oakenfull (2001). One possible mechanism was that soyasaponins may 
inhibit the intestinal absorption of cholesterol by forming large complexes with cholesterol. 
Another possible mechanism was that soyasaponins may inhibit the bile acid absorption from 
the intestine and then increase fecal excretion of bile acids. As a result of inhibiting the 
intestinal absorption of bile acids, soyasaponins lower plasma total cholesterol by enhancing 
bile acid synthesis. 
G. Role of soy components in other cardiovascular disease risk factors 
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Soy consumption has been shown to improve cardiovascular health or modify other 
cardiovascular disease risk factors except plasma lipid profiles including inhibition oxidation 
of LDL, improvement of arterial function, and reduction of platelet aggregation and serotonin 
content. 
G. 1 LDL oxidation 
The oxidized LDL particle is thought to be more atherogenic than the native LDL 
particle. Soy isoflavones have been reported to inhibit the oxidation of LDL (Kapiotis et al., 
1997; Yamakoshi et al., 2000; Jenkins et al., 2000 and 2003) and enhance the resistance of 
LDL to oxidation (de Whalley et al., 1990; Kanazawa et al., 1995, Tikkanen et al., 1998; 
Wiseman et al., 2000). Yamakoshi et al. (2000) reported that the atherosclerotic lesion of 
rabbits fed the isoflavone aglycone-rich extract (providing approximately 1.8 mmol or 5.6 
mmol total isoflavones/kg diet) plus 1% cholesterol showed fewer oxidized LDL-positive 
macrophage-derived foam cells compared with that of rabbits fed 1% cholesterol alone. 
Hyperlipidemic men and postmenopausal women consuming soy protein foods (33 g soy 
protein/d) containing 86 mg isoflavones (approximately 0.7 mmol/kg diet) reduced the 
concentration of the oxidized LDL fraction (Jenkins et al., 2000). Wiseman et al. (2000) 
found that subjects (19 women and 5 men, aged 19-40 y) who consumed the textured soy 
protein containing 56 mg isoflavones (approximately 0.42 mmol/kg diet) had longer lag time 
for copper-ion-induced LDL oxidation compared with subjects who consumed a low level of 
isoflavones (approximately 0.014 mmol/kg diet). It seems that antioxidant properties of soy 
isoflavones inhibit the oxidation of LDL and increase oxidative resistance of lipoproteins, 
thereby exerting an antiatherosclerotic effect. 
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G. 2 Arterial function 
The effects of soy and soy components on arterial function are inconsistent 
Constriction of coronary arteries following acetylcholine injection was inhibited in 
premeopausal macaques fed isolated soy protein containing isoflavones (approximately 1.13 
mmol /kg diet) compared with isoflavone-depleted isolated soy protein (containing 
approximately 0.11 mmol total isoflavones/kg diet). Arteries dilated in macaques fed isolated 
soy protein containing isoflavones (Honore et al., 1997). Compared with placebo, flow-
mediated dilation was not significantly changed in postmenopausal women either consuming 
40 g isolated soy protein with 118 mg isoflavones for 3 months (Teede et al., 2001) or taking 
80 mg soybean phytoestrogen tablets daily (Simons et al., 2000). Nestel et al. (1997) reported 
that soy isoflavone tablets (80 mg/d) improved systemic arterial compliance in menopausal 
and perimenopausal women. It seems that soy isoflavones may affect vascular reactivity, 
although more evidence is needed to confirm the potential health benefits of using soy and 
soy components on arterial function. 
G. 3 Platelet aggregation and serotonin storage 
Reduced platelet aggregation is important in the prevention of CVD. Using an in vitro 
system, platelets obtained from animals fed intact soy protein isolate containing isoflavones 
showed lower platelet aggregation in response to thrombin and serotonin compared with 
platelets from those fed alcohol-washed soy protein isolate (Williams and Clarkson 1998). 
These investigators found that blood flow was significantly less in female rhesus monkeys 
fed isoflavone-depleted soy protein (providing approximately 0.005 mmol/kg diet) compared 
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with those fed soy protein with isoflavones (providing approximately 1.0 mmol/kg diet) 
Helmeste and Tang (1995) reported that uptake of serotonin in platelets was decreased by 
genistein. These findings suggested that soy isoflavones may a play role in reducing 
serotonin storage and in inhibiting platelet aggregation. 
H. Role of soy components in atherosclerosis 
The formation of atherosclerotic lesions is initiated by some endothelial injury. The 
cellular infiltration and proliferation is caused by injury and then contributes to the advanced 
lesion formation. Several studies suggested that isolated soy protein with isoflavones 
reduced atherosclerosis compared with isoflavone-depleted isolated soy protein (Clarkson et 
al., 2001; Adams et al., 2002; Anthony et al., 1997; Kirk et al., 1998). Thus, the potential 
mechanisms of soy isoflavones in preventing atherosclerosis may include beneficial effects 
on plasma lipid concentrations, antioxidant effects, effects on thrombus formation, 
antiproliferative and antimigratory effects on smooth muscle cells, and maintenance of 
normal vascular reactivity. Considerable evidence suggests that soy protein with isoflavones 
has an antiatherosclerotic effect and inhibition of atherosclerosis is likely mediated by 
lowering plasma lipid concentrations and inhibiting the oxidation of LDL or enhancing the 
resistance of LDL to oxidation. 
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BETA-CONGLYCININ DEFICIENT IN SOY ISOFLAVONES AND 
SOYASAPONINS DID NOT LOWER PLASMA CONCENTRATIONS 
OF LIPOPROTEINS AND CHOLESTEROL OVER TIME IN MILDLY 
HYPERCHOLESTEROLEMIC WOMEN 
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Sun-Ok Lee, V. Smith, D. Rickert, M. Reuber, K. Hanson, S Lebepe-Mazur, L. Johnson, 
D.L. Alekel, D. Lewis, Suzanne Hendrich, Patricia A. Murphy 
ABSTRACT 
To clarify which components of dietary soy protein reduce plasma cholesterol 
concentrations in hypercholesterolemic individuals, 52 women with low-density lipoprotein 
(LDL) cholesterol levels ranging from 2.58 to 5.17 mmol/L were randomly assigned to one 
of three groups for 28 days. Subjects received one muffin per day of the following 
composition depending upon treatment group: 1) 28 g of casein as the protein source; 2) 28 
g of (3-conglycinin, a major soybean protein, containing 22 fitnol of isoflavones and 23 jimol 
of saponins; or 3) 28 g of (3-conglycinin containing 218 |imol of isoflavones and 276 jxmol of 
saponins. At days 14 and 28, women fed (3-conglycinin containing high levels of isoflavones 
and saponins had significant decreases in total cholesterol by 6.5% and 6%, respectively, and 
LDL cholesterol by 9% and 8%, respectively, compared with day 0 (P < 0.05). In women fed 
casein, LDL cholesterol concentration was significantly decreased by 7.5% at day 28 
compared with day 0 (P < 0.05). No significant effects of dietary treatments on either bile 
acid or neutral sterol excretion in feces were found. (3-conglycinin low in isoflavones and 
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saponins was ineffective at lowering plasma cholesterol over time in mildly 
hypercholesterolemic women. This study suggests that isoflavones and saponins seem to be 
needed companions for (3-conglycinin to exert a cholesterol-lowering effect. The components 
associated with dietary casein that lower LDL cholesterol level remain to be determined. 
Keywords: (3-conglycinin, saponins, isoflavones 
INTRODUCTION 
Coronary heart disease (CHD) mortality and morbidity are major health problems in 
the United States (AHA, 2004). Increased blood cholesterol concentrations, specifically those 
of total or low-density lipoprotein (LDL) cholesterol, are associated with the development of 
atherosclerotic cardiovascular disease (CVD) (Law, 1999). Several studies have shown that a 
diet containing soy protein improves the plasma lipid profile of humans and animals (Potter 
et al., 1993; Bakhit et al., 1994; Anderson et al., 1995; Teixeira et al., 2000; Aoyama et al., 
2001; Moriyama et al., 2004; Duranti et al., 2004). A meta-analysis showed a significant 
relationship between soy protein consumption and decreased total and LDL cholesterol by 
9% and 13%, respectively, and lower risk of heart disease (Anderson et al., 1995). Aoyama et 
al. (2001) reported that a diet containing 20% (3-conglycinin, one of the two storage proteins 
in soybeans, significantly lowered plasma total cholesterol and triglyceride concentrations in 
male Wistar young and adult rats compared with a diet containing 20% casein. 
The bioactive components of soy protein responsible for the hypocholesterolemic 
effect have yet to be defined. Currently, there is great interest in phytoestrogen^ soy 
isoflavones, glycitein, genistein, and daidzein, regarding their possible role in lipid 
metabolism (Anthony et al., 1996 and 1997; Clarkson et al., 2001; Kirk et al., 1998; Honoré 
et al., 1997; Ni et al., 1999; Song et al., 2003; Merz-Demlow et al., 2000; Uesugi et al., 2002; 
Cassidy et al., 1995; Grouse et al., 1999; Wangen et al., 2001). Crouse et al. (1999) 
investigated the effects of feeding 25 g isolated soy protein containing different amounts of 
isoflavones for 9 weeks in moderately hypercholesterolemic men and women. Compared 
with casein, 25 g of isolated soy protein with 62 mg of isoflavone reduced plasma total and 
LDL cholesterol concentration. In subjects with LDL cholesterol above the median (> 4.24 
mmol/L) of the population studied, isolated soy protein with 37 mg of isoflavones also 
reduced both total and LDL cholesterol compared with casein. Wangen et al. (2001) reported 
that 63 g of isolated soy protein per day containing 132 mg of isoflavones reduced plasma 
LDL cholesterol compared with isolated soy protein containing 7 mg of isoflavones in mildly 
hypercholesterolemic postmenopausal women 
Saponins, another class of phytochemicals associated with soy protein, also have been 
suggested as a plasma cholesterol-lowering factor (Oakenfull and Sidhu, 1990; Potter et al., 
1979; Newman et al., 1958; Fukui et al., 200). Sidhu and Oakenfull (1986) showed that 
various saponins added to the diet at 10% by weight reduced blood cholesterol in rats by 
increasing excretion of bile acids or decreasing cholesterol absorption. 
Although the hypocholesterolemic effect of soy protein is documented in many 
species including humans, the mechanism has not been demonstrated conclusively. Possible 
mechanisms for soy protein-induced changes in blood lipids include a decrease in the 
intestinal absorption of dietary cholesterol or bile acids (Potter, 1998; Greaves et al., 2000), 
or changes in the hepatic metabolism of cholesterol and lipoproteins via change in 
apolipoprotein content or composition (Samman et al., 1989; Huff and Carroll, 1980; Lovati 
et al., 1992; Duranti et al., 2004). Samman et al. (1989) found that a 57% reduction of LDL 
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cholesterol concentration in New Zealand white rabbits fed soy protein compared with casein 
was primarily due to an enhancement in receptor-mediated catabolism of LDL-apo B. In 
addition, an increase in bile acid and neutral steroid excretion may decrease hepatic 
cholesterol reserves and increase hepatic LDL receptor activity, thereby decreasing plasma 
LDL cholesterol concentration (Sitori et al., 1984; Beynen, 1990; Nagaoka et al., 1999; 
Jaskiewicz et al., 1987; Gaddi et al., 1991). Lower serum total cholesterol in rats fed soy 
protein peptic hydrolysate, compared to those fed casein tryptic hydrolysate, was associated 
with increased fecal excretion of total steroids (Nagaoka et al., 1999). 
In view of the growing attention to the mechanisms of the hypocholesterolemic 
response to soy proteins, it was of interest to examine specific soy proteins and related 
components for their ability to reduce plasma cholesterol concentrations. Peptides from (3-
conglycinin (7S globulin) up-regulated hepatic LDL receptors in human hepatoma (HepG2) 
cells while glycinin (1 IS globulin) peptides had no effect (Lovati et al., 1992). Manzoni et al. 
(2003) also reported LDL receptor upregulation in HepG2 cells induced by the a' subunit of 
7S globulin. Purified a' subunit from soybean 7S globulin significantly reduced plasma total 
cholesterol and triglycerides and increased liver P-VLDL receptor expression in rats (Duranti 
et al., 2004). This study was designed to examine the effect of the major soy protein, P-
conglycinin, containing high or low levels of isoflavones and saponins on plasma total 
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Mildly 
hypercholesterolemic women consumed common baked products to determine if (3-
conglycinin affects circulating cholesterol by increasing excretion of fecal bile acids and 
neutral sterols. 
SUBJECTS AND METHODS 
Preparation of p-conglycinin 
(3-conglycinin, a major soy storage protein, was prepared from defatted soy flakes by 
scaling up a process developed by Wu et al. (2000). Defatted soy flakes at 90 PDI (protein 
dispersibility index; Cargill Inc., Minneapolis, MN) or 70 PDI (Archer Daniels Midland, 
Decatur, IL) were combined with water at a ratio of 1 part flakes : 8 parts water. The pH was 
adjusted to 8.5 with 2 TVNaOH and the slurry was stirred for 1 h at 20°C to solubilize the soy 
protein. The solubilized protein was separated from the insoluble fraction by passing the 
slurry through a Sharpies P660 continuous centrifuge (Alfa Laval Separation Inc., 
Warminster, PA) using 5700 rpm bowl speed and 4000 rpm backdrive pinion speed. The 
slurry was fed to the centrifuge using a Moyno-type transfer pump (Electric Pump, model 
IFFCA S SE SAA, Des Moines, IA) with a 250 rpm pump speed. Sharpies centrifuging 
yielded an insoluble fraction and an extract fraction. The insoluble residue was re-extracted 
at a ratio of 1 part flakes : 5 parts water, and this slurry was passed through the Sharpies 
centrifuge again. The first extract and resulting second extract were combined, treated with 
sodium bisulfite (0.98 g/L or -10 mM SO2), and adjusted to pH 6.4 using 2 #HC1. After 
chilling overnight at 7°C, the protein solution was centrifuged using an Alfa Laval BTPX 
205 disc centrifuge (Alfa Laval Separation Inc., Warminster, PA) at 9800 rpm bowl speed 
and 420 rpm transfer pump speed. Sodium chloride was added to the supernatant fraction of 
this centrifuge pass to adjust the ionic strength of the (3-conglycinin-containing supernatant 
fraction to 0.25 M and 2 A^HCl was added to adjust the pH of the solution to 5.0. The 
solution was stirred for 1 h at 7°C, then passed through the Alfa Laval centrifuge. To the 
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supernatant of this centrifuge pass, a volume of water twice the amount of supernatant was 
added to adjust the ionic strength of the supernatant, and the supernatant was adjusted to pH 
4.8 using 2 ;VHC1. After chilling overnight at 7°C, the precipitated (3-conglycinin was 
separated with the Alfa Laval centrifuge as above. The (3-conglycinin precipitate was 
redissolved in an aqueous solution and desalted with a Feed and Bleed Membrane Filtration 
system (Model SRT-50; North Carolina SRT Inc., Cary, NC) and 30-KD regenerated 
cellulose membrane (North Carolina SRT Inc., Cary, NC). Diafiltration was performed until 
an amount of permeate equal to five times the volume of the (3-conglycinin precipitate had 
been collected. The retentate was dried in an Anhydro compact spray-dryer (APV Crepaco 
Inc., Attleboro Falls, MA) with an air inlet temperature of 180°C and an air outlet 
temperature of 85 °C. 
Protein content was determined by measuring the nitrogen content using the micro-
Kjeldahl method (AOAC, 1999, methods 988.05 and 960.52). The nitrogen conversion factor 
used for (3-conglycinin was 6.37. The protein content of the (3-conglycinin was 85-88%. 
Purity of the (3-conglycinin was > 85% as measured by urea-sodium-dodecylsulfate-
polyacrylamide gel in electrophoresis (SDS-PAGE). Protein moisture contents were 
measured using a forced-air oven (Fischer Scientific Isotemp 750°F, Fischer Scientific, 
Pittsburgh, PA) and averaged 10-11%. 
Extraction of isoflavones and saponins from {3-conglycinin 
(3-conglycinin deficient in isoflavones and saponins was prepared by extracting (3-
conglycinin, 1 g (3-conglycinin : 3 ml of 70% ethanol (food grade) in water. The mixture was 
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stirred for 2-3 h and decanted. Extraction of P-conglycinin was carried out 5 times to reduce 
the isoflavone concentration to 20 p.g/g of the P-conglycinin fraction. P-conglycinin deficient 
in isoflavones and saponins was dried using a Hobart convection oven (Hobart Mfg. Co., 
Troy, OH) at 60°C for 2 h and then was ground to a homogenous powder in a Coffee Mate 
coffee grinder (Black and Decker Inc., Shelton, CT). 
Subjects 
Study procedures were approved by the Iowa State University Human Subject 
Protection Committee. About two hundred women (18-40 y of age) were recruited from the 
Iowa State University campus and surrounding areas and initially screened their plasma lipid 
concentrations. The women were interviewed in person and completed detailed 
questionnaires on health and medical history, typical food intake, and physical activity at the 
beginning of the study. A total of 72 healthy women selected had LDL cholesterol at 
screening between 2.58 mmol/L and 5.17 mmol/L. All subjects were non-smokers, did not 
consume soy products in their usual diets, and did not have diabetes mellitus, or other 
chronic illness that might affect blood lipid concentrations. This study was conducted with 2 
separate cohorts, each of which participated in a 38 days feeding study including a 10 day 
washout period: cohort 1 during the fall of 1999 (n = 36), cohort 2 during the spring of 2000 
(n = 36). For cohorts 1 and 2, the numbers of subjects who dropped out were 15 and 5, 
respectively. Thirteen subjects who failed the inclusion criteria, by having LDL cholesterol 
concentrations lower than 2.58 mmol/L, were excluded at day 0. Three subjects failed to 
comply with required procedures and the other 4 subjects chose to withdraw from the study. 
Fifty-two subjects completed the study. All subjects who met the inclusion criteria and 
wanted to participate signed informed consent forms before they started the study. 
Diet and study design 
All subjects received detailed dietary instructions to avoid foods known to be rich in 
soy protein, isoflavones or other phytoestrogens, or saponins, such as soy beverage, tofu, 
flaxseed, garbanzo beans, bean sprouts, and frozen food products containing soy protein. 
During the 10 day washout periods, they were instructed to consume a diet composed of < 
30% energy from fat (polyunsaturated fat: monounsaturated fat: saturated fat ratio of 10: 10: 
10), < 15% from protein, < 55% from carbohydrate, and 15-20 g dietary fiber/day (step I 
diet). After this 10 day washout period, subjects were randomly assigned to 3 experimental 
groups. The study used a double-blind design; subjects did not know to which of the groups 
they were assigned, nor did the investigator. The women received 28 g protein/d which 
included 1) casein (New Zealand Milk Products, Inc., Santa Rosa, CA) as the control, 2) (3-
conglycinin containing 22 jamol of isoflavones and 23 gmol of saponins, or 3) P-conglycinin 
containing 218 (imol of isoflavones and 276 |imol of saponins, for 28 days. Test proteins 
were incorporated into a muffin which the subject received at breakfast 7 d/wk. The 
micromole concentrations of isoflavones/subject per day (Fig.l), as daidzein, genistein, and 
glycitein, and the concentrations of soyasaponins ag, Pg, I, and Il/subject per day (Fig.2) 
were calculated based on analytical data described below. Six different flavors of muffin 
(apple-cinnamon, banana, pumpkin spice, blueberry, cranberry-orange, and dried fruit) were 
served during the study. All the participants were required to eat the same flavor each 
morning. Their consumption of soy muffin was monitored 5 times/wk and subjects were 
reminded to consume one muffin in its entirety each weekend day. 
Analysis of isoflavone content in muffins 
Two grams of dried, finely ground muffin was extracted with 10 mL of acetonitrile 
and 7 mL of distilled water for 2 hours at room temperature. The extract was filtered through 
Whatman No. 42 filter paper. The filtrate was collected in a round-bottom flask and dried in 
a rotary evaporator (Buchler Instrument, Fort Lee, NJ) at < 30°C. The dried residues were 
dissolved in 80% aqueous methanol and made up to 10 mL in the volumetric flask. An 
aliquot was vortexed and filtered through a 0.45 mm PTFE filter (Alltech Associates Inc., 
Deerfield, IL) and analyzed by HPLC. The soy isoflavone content in the muffins were 
measured by HPLC using the method previously described (Murphy et al., 1999). 
Analysis of saponin content in muffins 
Four grams of dried, ground muffin was extracted by stirring with 100 mL of 70% 
aqueous ethanol for 2.5 h at room temperature. The extract was filtered through Whatman 
No. 42 filter paper and evaporated to dryness below 30°C. The dried residues were dissolved 
in 80% aqueous methanol and made up to 10 mL in the volumetric flask. An aliquot was 
vortexed and filtered through a 0.45 mm PTFE filter (Alltech Associates Inc., Deerfield, IL) 
prior to HPLC analysis. The content of saponins in the muffins were determined by HPLC 
system as previously reported by Hu et al. (2002). 
Plasma lipid analysis 
Blood samples were collected at day 0 (baseline), day 14, and day 28 during the study 
after a 12-hr overnight fast. Blood was drawn into tubes containing EDTA, set at room 
temperature for 30 min to allow coagulation, and centrifuged at 3000 x g for 15 min at 18°C 
to obtain serum. Serum total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride 
were analyzed enzymatically by Quest Diagnostics (Des Moines, IA), a certified clinical 
laboratory. LDL-cholesterol was calculated by Quest Diagnostics using the Friedewald 
formula (Friedewald et al., 1972). 
Analysis of fecal bile acids and neutral sterols 
On day 23 of dietary treatments, all subjects were given two capsules containing 
carmine red dye marker (first marker) and 24 hours later they received two capsules 
containing sterilized yellow ceramic beads (second marker). Feces were collected from the 
time that the red marker appeared in feces until the time that yellow beads appeared. 
Quantitation of bile acids and neutral sterols in human feces was performed according 
to the method of Batta et al. (1999). Two hundred pL of n-butanol which contained 
hyocholic acid and 5a-cholestane (internal standards) and 50 pL of concentrated 
hydrochloric acid were added to 15 mg freeze-dried fecal samples and to the standards (10 
|j.g of each bile acid and 20 |_ig of each neutral sterol). The mixture was heated at 60°C for 4 h 
and then solvents evaporated at 60°C under N2. The butyl esterified bile acids, the neutral 
sterol standards, and fecal samples were reacted with 100 pL of Sil-prep (trimethyl silylation 
reagent, Alltech Associates Inc., Deerfield, IL) for 30 min at 55°C. Solvents were evaporated 
60 
at 55°C under N2. Trimethyl silyl ether derivative of fecal samples and standards were 
resuspended in 200 |iL hexane, centrifuged to separate the fecal debris, and injected 2 |J.L 
onto the gas-chromatography column. 
Analysis was performed using a Varian Chrompak CP-Sil 5 CB Low Bleed/MS fused 
silica capillary column, 25 M x 0.25 mm ID x 0.25 mm film thickness (Supelco Park, 
Bellefonte, PA) installed in a Hewlett Packard 6890 gas chromatograph equipped with a 
flame ionization detector and autosampler. Carrier gas was helium at a flow rate of 1.5 
mL/min. Injector temperature was 260°C and detector temperature was 290°C. Peaks were 
identified by comparing retention times with those of authentic bile acids (hyodeoxycholic 
acid, deoxycholic acid, hyocholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic 
acid, ursocholic acid, and lithocholic acid) or neutral sterol standards (coprostanol, 
campesterol, stigmasterol, stigmastanol, cholestanone, cholesterol, cholestenone, cholestane, 
^-sitosterol, lanosterol, and lathosterol) (Steraloids Inc., Newport, RI). The weight 
percentage of each bile acid, fatty acid, and neutral sterol was determined by integration of 
the peak areas. 
Other measurements 
Typical intake of foods was used to assess energy needs in order to provide each 
subject with appropriate dietary guidelines. Twenty-four hour food records were collected at 
baseline, day 14, and day 28. All food records were analyzed for daily nutrient intake using 
Nutritionist V for Windows, version 1.7 (First Databank, The Hearst Corporation, San 
Bruno, CA). Physical activity during the previous seven days assessed using the Five-City 
Project physical activity recall (Sallis et al., 1985). Percentage body fat was assessed by dual-
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energy X-ray (QDR-2000+; Hologic, Waltham, MA) after 28 day treatment period. Body 
weight and body mass index (BMI) were measured at the end of the 28 day feeding study. 
Statistical analysis 
All statistical analyses were conducted with the Statistical Analysis System (SAS, 
Release 8.2, SAS Institute Inc, Gary, NC). Values were expressed as means ± SD. One-way 
ANOVA was used to determine the relationship between dietary treatments, age, body 
weight, BMI, physical activity, fecal bile acids and neutral sterols, blood lipid profiles and 
treatment. Results were considered significant at P < 0.05. Pairwise comparisons between 
means were performed using Tukey's procedure. Tukey's procedure was selected because it 
consecutively controls for type I error. 
RESULTS 
Body weight, body mass index, physical activity, and body fat content 
The final mean body weights were 74.7 + 22.7 kg, 69.5 + 8.4 kg, and 71.7 + 14.7 kg 
for the groups fed casein, (3-conglycinin containing high levels of isoflavones and saponins 
((3-conglycinin+), and (3-conglycinin containing low levels of isoflavones and saponins ({3-
conglycinin-) diets, respectively, and were not significantly different (P < 0.05). There were 
no significant differences between treatment groups in BMI, physical activity, or percentage 
body fat (P < 0.05) (Table 1). 
Dietary intake 
Consumption of muffins containing casein or 3-conglycinin was well accepted by the 
subjects. No significant differences were found among the different groups for total fatty 
acids, saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids 
intakes (P < 0.05) (Table 2). Polyunsaturated fatty acid intake increased in all the groups 
between baseline and both days 14 and 28. There were no significant differences between 
days 14 and 28 for polyunsaturated fatty acid intake (Table 2). The intakes of other 
macronutrients did not differ among the groups during the study. 
Effects of soy protein on plasma lipids concentrations 
At baseline, day 14, or day 28, subjects fed 3-conglycinin containing low or high 
levels of isoflavones and saponins did not have significantly altered plasma lipids, total 
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and ratio of total cholesterol to 
HDL cholesterol, compared with the group fed casein (Table 3). At days 14 and 28, subjects 
fed 3-conglycinin containing high levels of isoflavones and saponins had significantly lower 
total plasma cholesterol (6.5% and 6%, respectively) and LDL cholesterol (9% and 8%, 
respectively) compared with day 0 (P < 0.05) (Table 3). In subjects fed casein, LDL 
cholesterol was significantly decreased by 7.7% at day 28 compared with day 0 (P < 0.05) 
(Table 3). 
When compared with day 0 (baseline), the ratio of total to HDL cholesterol was 
significantly lower at days 14 and 28 (7.8% and 7.3%, respectively) in women who 
consumed 3-conglycinin containing high levels of isoflavones and saponins (P < 0.05) (Table 
3). The ratio of total to HDL cholesterol was significantly decreased by 7.8% at day 14 
compared with day 0 in women who consumed casein (P < 0.05) (Table 3). 
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Fecal bile acids and neutral sterols 
There were no significant effects of the dietary treatments on either bile acid or 
neutral sterol outputs (P < 0.05) (Fig.3). The mean value of bile acid and neutral sterol 
outputs tended to be greater in the soy protein groups compared with the casein group. 
DISCUSSION 
The amount of soy protein per day (28 g) fed in this study was similar to the 
qualifying amount of soy protein (25 g) for the Food and Drug Administration (FDA)-
approved health claim that soy protein lowers blood cholesterol (1999). In this study, feeding 
p-conglycinin containing low or high levels of isoflavones and saponins did not significantly 
alter plasma lipids, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, or ratio 
of total to HDL cholesterol, compared with the group fed casein at any time point. Although 
the majority of the literature shows that the plasma cholesterol lowering associated with soy 
protein intake occurs mainly in the LDL fraction (Teixeira et al., 2000; Sirtori et al., 1984; 
Carroll 1991; Erdman and Fordyce 1989), our results showed the lack of effect of soy protein 
on plasma total cholesterol and LDL cholesterol, in agreement with other human studies 
(Teede et al., 2001; Dewell et al., 2002; Nest el et al., 1997; Hodgson et al., 1998). In the 
present study, P-conglycinin containing low or high levels of isoflavones and saponins 
compared with casein at concentrations any time point (data not shown) did not significantly 
alter plasma lipids in subjects with LDL cholesterol above the median (> 4.02 mmol/L) of the 
population studied. 
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A meta-analysis of data from 38 clinical studies indicated that the changes in plasma 
total and LDL cholesterol concentrations were directly related to the initial plasma 
cholesterol concentrations (Anderson et al., 1995). Subjects with normal cholesterol levels 
(5.2 mmol/L) or mild hypercholesterolemia (initial values of 5.2 to 6.6 mmol/L) had 
nonsignificant reductions of 3 .3% and 4.4%, respectively, while receiving the soy protein 
diet. Subjects with moderate hypercholesterolemia (initial values of 6.7 to 8.6 mmol/L) or 
with severe hypercholesterolemia (initial values above 8.66 mmol/L) had significant 
reductions of 7.4% and 19.6%, respectively. The pattern of changes in plasma LDL 
cholesterol was similar to the pattern for plasma total cholesterol concentrations. Potter et al. 
(1993) showed that 50 g of isolated soy protein/d significantly lowered total and LDL 
cholesterol levels by 12% and 11.5%, respectively, compared with nonfat dry milk in mildly 
hypercholesterolemic men with an average baseline cholesterol concentration of 5.9 mmol/L. 
Teixeira et al. (2000) reported that 20 g of isolated soy protein did not significantly change 
the concentrations of total and non-HDL cholesterol at week 3 in moderately 
hypercholesterolemic men aged 23-74 y (total cholesterol between 5.70 mmol/L and 7.70 
mmol/L). At week 6, 20 g of isolated soy protein significantly decreased total and non-HDL 
cholesterol concentrations by 6.8% and 7.9%, respectively, compared with casein. Either 
consumption of greater amounts of soy protein/d for shorter periods of time or 28 g of soy 
protein/d fed for longer periods of time may be needed to achieve significant lowering of 
plasma lipids concentrations compared with casein. 
The dietary P S ratio may have masked the effectiveness of soy protein in this study. 
Widhalm (1986) reported that a linoleic acid-rich soy protein diet resulted in marked 
reductions in plasma cholesterol (30-32%), LDL cholesterol (36-38%), HDL cholesterol (26-
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28%), and apo B (30-33%) compared with cow-milk protein diet in children heterozygous for 
familial hypercholesterolemia. However, Laurin et al. (1991) found that children with 
familial hypercholesterolemia fed soy protein had no changes in plasma cholesterol, LDL 
cholesterol, or apolipoprotein concentrations compared with those fed cow-milk protein. It 
seems likely that the lower P S in Laurin's study (P:S=0.3) compared with Widhalm's 
(P:S=1.5) may partly explain the different effects of soy protein. Sirtori et al. (1979) showed 
that a soy protein diet containing a very low P S (0.1) is less effective for inducing significant 
responses in plasma total and LDL cholesterol. The P S ratio of 0.7, as determined by food 
records during the treatment period in this study, at day 14 and 28 may have masked a small 
effect of P-conglycinin containing high levels of isoflavones and saponins to lower plasma 
total and LDL cholesterol concentrations. Increased polyunsaturated fatty acids over time in 
all treatments may be due in part to consumption of muffin containing vegetable oil. 
We observed that subjects fed P-conglycinin containing high levels of isoflavones 
and saponins had significantly decreased plasma total and LDL cholesterol concentrations at 
days 14 and 28 compared with day 0. There were no significant differences in plasma total 
and LDL cholesterol between casein and P-conglycinin containing high levels of isoflavones 
and saponins at any time point. Grouse et al. (1999) reported that consuming 25 g isolated 
soy protein with 62 mg of isoflavones for 9 weeks significantly lowered plasma total and 
LDL cholesterol by 4% and 6%, respectively, compared with casein in moderately 
hypercholesterolemic subjects (initial LDL cholesterol levels between 3.62 and 5.17 
mmol/L). In the present study, 28 g of P-conglycinin containing approximately 55 mg of 
isoflavones was consumed for 4 week and the initial LDL cholesterol of subjects was 
between 2.58 and 5 .17 mmol/L. If a higher intake of isoflavones had been consumed for a 
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longer period, or subjects had high initial cholesterol concentrations, perhaps a significant 
improvement in plasma total and LDL cholesterol would have been seen in these subjects fed 
(3-conglycinin containing high levels of isoflavones and saponins. (3-conglycinin containing 
low levels of isoflavones and saponins did not lower plasma cholesterol levels over time in 
this study. It may have been possible that the protein structure was damaged during the 
ethanol-washing of p-conglycinin, thus limiting the P-conglycinin efficacy in lowering 
plasma lipid concentrations. However, other studies showed that alcohol-washed soy protein 
was effective in lowering plasma lipid concentrations (Song et al., 2003;.Blair et al., 2002; 
Balmir et al., 1996). Compared with casein, ethanol-washed isolated soy protein lowered 
plasma total and non-HDL cholesterol levels in male and female hamsters (Song et al., 
2003). Ethanol-acetone extracted soy protein significantly lowered plasma total and non-
HDL cholesterol in rats compared with casein (Balmir et al., 1996). Further studies are 
needed to investigate the impact of alcohol extraction on the bioactivity of soy protein. 
An unexpected finding in this study was that LDL cholesterol was significantly 
decreased at day 28 compared with day 0 in women fed casein. Gardner et al. (2001) 
observed that a group fed milk protein had nonsignificant effects in reducing plasma total and 
LDL cholesterol over time. The changes in plasma total and LDL cholesterol were not 
significantly different between the milk protein and the isolated soy protein containing either 
trace amounts of isoflavones or 80 mg aglycone isoflavones. It seems that unidentified 
components associated with the casein may have caused this effect. Van der Meer et al. 
(1985) showed that at the normal calcium level (0.84%, w/w), casein, as compared with soy 
protein, increased the concentration in serum of total and free cholesterol and the ratio of free 
cholesterol to phospholipid in young male rabbits. An increased amount of dietary calcium 
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(1.44%, w/w) inhibited the effects of casein to increase intestinal phosphate absorption and 
the serum lipid parameters. In contrast, calcium levels did not change these parameters in 
rabbits fed a soy protein diet. In the present study, there were no apparent differences in 
calcium intake among treatment groups, which ranged from 900 to 1100 mg per day. More 
research is needed to explain the cholesterol-lowering effect of casein. HDL cholesterol and 
triglycerides were not significantly affected by dietary treatment (Table 3), consistent with 
other studies (Teixeira et al., 2000; Potter et al., 1993; Crouse et al., 1999). 
Our data showed that subjects fed P-conglycinin containing high levels of isoflavones 
and saponins had significantly decreased the ratio of total to HDL cholesterol at days 14 and 
28 compared with day 0. Because subjects fed P-conglycinin containing low levels of 
isoflavones and saponins had lower baseline ratio of total to HDL cholesterol concentrations 
than other groups (Table 3), albeit not statistically significant, it might have been less likely 
to see a significant difference in this ratio with this treatment. 
It is not well known how dietary soy protein induces changes in blood lipid 
concentrations. Some investigators have reported that dietary soy protein increased excretion 
of fecal bile acids and neutral steroids (Beynen 1990; Schwerin et al., 2002 Wright and Salter 
1998; Nagaoka et al., 1999). Wright and Salter (1998) showed that fecal bile acids were 2-
fold greater in soy protein-fed hamsters than in hamsters fed a casein diet. Hepatic 
cholesterol decreased by 32%, as the amount of soy protein consumed increased from 16.3% 
to 36.3%, suggesting that it is this pool of cholesterol that is used to replace the excreted bile 
acids. Nagaoka et al. (1999) reported that serum total cholesterol was significantly lower 
(46%) in rats fed soy protein peptic hydrolysate with bound phospholipids (SPHP) than in 
those fed casein. Fecal excretion of total steroids (acidic steroids plus neutral steroids) was 2-
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fold higher in rats fed SPHP than in those fed casein. Our results showed no significant 
treatment effects on bile acid and neutral sterol excretion. However, the mean values of both 
bile acid and neutral sterol outputs tended to be higher in women fed P-conglycinin 
containing low or high levels of isoflavones and saponins compared with women fed casein. 
The lack of an effect of soy protein on bile acid and neutral sterol excretions is consistent 
with the fact that feeding P-conglycinin did not significantly alter plasma lipids compared 
with subjects fed casein in the present study. 
In summary, our data in mildly hypercholesterolemic, premenopausal women 
demonstrated a significant reduction of plasma total and LDL-cholesterol over time during 
ingestion of P-conglycinin only was at contained high levels of isoflavones and saponins. A 
slight but nonsignificant increase in bile acid and neutral sterol outputs may have contributed 
to these changes, but this possibility will require further study. The respective roles in 
cholesterol metabolism of isoflavones, saponins, and other non-protein components 
associated with soy protein deserve more investigation. 
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Table 1. The means of body mass index (kg/m2). body fat (% of weight), and physical activity 
(kcal/kg/d) among treatments after 28 d treatment period1 
Groups N Body mass index Body fat Physical activity 
(kg/ m2) (%) (kcal/kg/d) 
Casein 18 26.7 + 7.4 31.6 ±5.8 35.1 ±1.9 
P-conglycinin (+) 16 24.6 ±3.1 31.1 ±4.4 35.9 ± 4.3 
P-conglycinin (-) 18 25.6 ± 4.8 30.9 ± 5.2 34.5 ±1.6 
1 Values represent means ± SD. 
(3-conglycinin (+): p-conglycinin containing isoflavones and saponins 
P-conglycinin (-): p-conglycinin deficient in isoflavones and saponins 
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Table 2. The means of total fatty acids, saturated fatty acids, monosaturated fatty acids, and 
polyunsaturated fatty acids (all as mg/day) from 24-hour food record data compared across 
treatments1 
Casein P-conglycinin (+) P-conglycinin (-) 
(n=18) (n=16) (n=18) 
Total fatty acids' 
Baseline 50 ±28 62 ±20 64 ±30 
Day 14 61 ±21 65 ±22 71 ±25 
Day 28 55 ±32 64 ±24 65 ±22 
Saturated fatty acids3 
Baseline 17 ± 11 1 22 ± 11 22 ±13 
Day 14 19 ±9 20 ± 10 20 + 7 
Day 28 19 ± 12 18 ± 10 21 ±11 
Monounsaturated 
fatty acids3 
Baseline 14 + 9 19 ± 7 16 ± 12 
Day 14 16 ±7 18 ± 8 18 ± 9 
Day 28 13 ±9 19 ± 12 18 ± 7 
Polyunsaturated 
fatty acids3 
Baseline 9±4 9 ± 4 9 + 6 
Day 14 15 ± 4a 15 ±5a 19+ 10" 
Day 28 13 ± 9a 14 + 5a 15 + 6" 
1 Values represent means ± SD. 
2p For females 19-40 years, recommended total fatty acid intake is 73 gm/d, saturated fatty acid or 
monounsaturated fatty acid or polyunsaturated fatty acid is 24 gm/d. 
a Significantly different from baseline at p < 0.05 
P-conglycinin (+): p-conglycinin containing isoflavones and saponins 
P-conglycinin (-). p-conglycinin deficient in isoflavones and saponins 
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Table 3. Lipid and lipoprotein concentrations at day 0,14, and 28 in participants consuming 28 
g of P-conglycinin containing variable amounts of isoflavones and saponins or 28 g of casein1 
Casein P-conglycinin (+) p-conglycinin (-) 
(n=18) (n=16) (n=18) 
Cholesterol (mmol/L) 
Baseline 
Day 14 
Day 28 
5.60 ±0.87 
5.44 ±0.91 
5.44 ±0.83 
5.48 + 0.68 
5.12 + 0.69' 
5.18 ±0.59' 
5.60 ± 1.03 
5.43 ±0.80 
5.42 ±0.86 
LDL (mmol/L) 
Baseline 
Dav 14 
Day 28 
3.62 ±0.65 
3.42 ±0.67 
3.34 ±0.60' 
3.62 + 0.65 
3.28 + 0.68' 
3.32 ±0.58" 
3.56 ±0.76 
3.43 ±0.68 
3.40 ±0.59 
HDL (mmol/L) 
Baseline 
Day 14 
Day 28 
1.36 ±0.53 
1.40 ±0.52 
1.36 ±0.50 
1.28 + 0.18 
1.31 + 0.18 
1.32 ± 0.19 
1.38 ±0.34 
1.40 ±0.35 
1.42 ±0.34 
Triglyceride (mmol/L) 
Baseline 
Dav 14 
Day 28 
1.38 ±0.50 
1.36 ±0.54 
1.61 ±0.63 
1.27 ±0.38 
1.18 ± 0.41 
1.19 ±0.40 
1.46 ±0.70 
1.31 + 0.61 
1.31 ±0.82 
Total/HDL cholesterol 
Baseline 
Dav 14 
Day 28 
4.54 ± 1.29 
4.18 ±0.98' 
4.39 ± 1.24 
4.34 + 0.79 
4.00 + 0.89' 
4.02 ±0.87' 
4.24 ± 1.02 
4.06 ±0.98 
3.99 ±0.98 
1 Values represent means ± SD. 
a Significantly different from baseline at p < 0.05 
(3-conglycinin (+): (3-conglycinin containing isoflavones and saponins 
(3-conglycinin (-): (3-conglycinin deficient in isoflavones and saponins 
77 
Fig 1. Isoflavone contents in a diet containing intact (3-conglycinin (P-conglycinin+) or 
ethanol-washed P-conglycinin (P-conglycinin-). 
Fig 2. Saponin contents in a diet containing intact P-conglycinin (P-conglycinin+) or 
ethanol-washed P-conglycinin (P-conglycinin-). 
Fig. 3 Mean values for fecal output of bile acids and neutral sterols in subjects who 
consumed P-conglycinin with isoflavones and saponins (P~conglycinin+) or P-
conglycinin deficient in soy isoflavones and saponins (P-conglycinin-).Bile acid and 
steroid excretion is expressed per gram feces (dry weight). Vales are represented as 
mean + SD. 
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THE ISOFLAVONE GLYCITEIN LOWERED PLASMA 
CHOLESTEROL IN FEMALE GOLDEN SYRIAN HAMSTERS 
A paper to be submitted to Experimental Biology and Medicine 
Sun-Ok Lee, Patricia A Murphy, and Suzanne Hendrich 
ABSTRACT 
The soybean isoflavones, daidzein, genistein, and glycitein, were hypothesized to act 
as cholesterol-lowering components, separate from soy protein. Pure synthetic daidzein, 
genistein, or glycitein was fed to female Golden Syrian hamsters (11-12 weeks of age, 10 
hamsters/treatment) for 4 weeks in a diet containing -37% of energy as fat (62% from 
coconut oil), 25% casein and 0.1% cholesterol. The content of each isoflavone was -30% 
less than the total amount of isoflavones in a diet based on 25% isolated soy protein, 0.9 
mmol/kg diet. Hamsters fed glycitein had significantly lower plasma total cholesterol by 15% 
and lower non-HDL cholesterol by 24% compared with those fed casein (P < 0.05). Daidzein 
and genistein's effects on these lipids did not differ from the effects of either casein or 
glycitein. Plasma HDL cholesterol and triglyceride concentrations were not significantly 
affected by dietary treatments. The percentage of ingested dose recovered in urine for each 
isoflavone was glycitein > daidzein > genistein (32.2% > 4.6% > 2.2%). These data suggest 
that glycitein's greater cholesterol-lowering effect was due to its greater bioavailability, as 
reflected in urinary recovery of glycitein compared with the other purified isoflavones. 
Keywords: daidzein, genistein, glycitein 
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INTRODUCTION 
Soy isoflavones are major phytoestrogens in soybeans and soy foods. There is a great 
interest in soy isoflavones, daidzein, genistein, and glycitein, regarding their possible effects 
on plasma lipid levels. The role of soy isoflavones in lowering plasma concentrations of 
lipoproteins and cholesterol has been studied in animals (Balmir, et al, 1996; Tovar-Palacio 
et al, 1998; Anthony et al, 1996 and 1997; Kirk et al, 1998; Ni et al, 1999; Clarkson et al, 
2001; Song et al, 2003) and humans (Grouse et al, 1999; Merz-Demlow et al, 2000; 
Gardner et al, 2001; Wangen et al, 2001). 
Animal studies showed that isolated soy protein containing isoflavones or alcohol 
extracts of soy protein rich in isoflavones have a greater hypocholesterolemic effect on 
plasma total and non-HDL cholesterol concentrations. Soy protein isolate (ISP) containing 
isoflavones (1.0 mmol/kg diet) significantly lowered plasma total and LDL+VLDL 
cholesterol concentrations in ovariectomized monkeys compared with isoflavones-depleted 
ISP (0.005 mmol/kg diet) (Clarkson et al, 2001). Balmir et al. (1996) reported a significant 
reduction in plasma LDL cholesterol in male hamsters fed diets containing intact ISP, ISP 
with added ethanol extract (providing 0.6 mmol total isoflavones/kg diet), or casein with soy 
ethanol extract (providing 0.3 mmol total isoflavones/kg diet) compared with those fed 
casein. Several human studies also reported that consumption of a high level of isoflavones 
in the diet have more effective in improving plasma lipid profiles. Crouse et al. (1999) found 
that consumption of 25 g isolated soy protein with 62 mg isoflavones (approximately 0.5 
mmol/kg diet) significantly reduced plasma total and LDL cholesterol concentrations 
compared with casein. Plasma LDL cholesterol concentration was significantly lowered in 
premenopausal women consuming 53 g isolated soy protein with 129 mg isoflavones 
(approximately 1.0 mmol/kg diet) compared with women consuming isolated soy protein 
contained 10 mg isoflavones (approximately 0.08 mmol/kg diet) (Merz-Demlow et al, 
2000). 
Recent studies investigated the cholesterol-lowering effects of pure synthetic 
isoflavones or isolated pure isoflavones from soybean fraction (Uesugi et al, 2001; Demonty 
et al, 2002; Nogowski et al, 1998; Song et al, 2003). Ovariectomized rats fed isolated pure 
isoflavone glycosides daidzin (25 or 50 mg/kg body weight/d) or genistin (50 mg/kg body 
weight/d) orally using a stomach tube showed significantly lower plasma total cholesterol 
and triglyceride concentrations compared with casein-fed rats (Uesugi et al, 2001). Plasma 
triglyceride was significantly lowered in Sprague-Dawley rats fed a mixture of synthetic 
daidzein and genistein (1.4 mmol/kg diet or -23.6 mg/kg body weight/d) compared with 
those fed casein (Demonty et al, 2002). Song et al. (2003) reported that hamsters fed pure 
synthetic daidzein (1.3 mmol/kg diet or -16 mg/kg body weight/d) had significantly lower 
plasma total and non-HDL cholesterol compared with those fed casein. 
Isoflavones contents in urine or plasma may be considered as a biological marker of 
soy consumption and it is relatively easy to quantify the amount of isoflavones. Xu et al. 
(1994) found that daidzein was more bioavailable than genistein, as reflected in urinary 
recovery of daidzein (21%) compared with that of genistein (9%). Zhang et al. (1999) 
reported that the average 48 h urinary recoveries of daidzein, glycitein, and genistein were 
approximately 52%, 47%, and 37%, respectively, suggesting that bioavailability of daidzein 
and glycitein were similar, both being greater than genistein. 
We hypothesized that soy isoflavones are responsible in large part for the beneficial 
effects of soy on plasma lipid concentrations and that glycitein may have more cholesterol-
lowering effects because glycitein is more absorbable compared with the other two purified 
isoflavones in hamsters, based on previous unreported studies in our laboratory. To test these 
hypotheses, we fed pure synthetic daidzein, genistein, or glycitein to hamsters and then 
measured plasma lipid concentrations and determined the association between urinary 
recovery of each isoflavone and plasma lipid concentrations. Hamsters were selected as an 
animal model because there are several similarities in cholesterol metabolism between 
hamsters and humans. Hamsters fed a diet enriched with saturated fat show a substantial 
increase in plasma total and LDL cholesterol (Terpstra et al, 1991). There is a comparable 
bile acid pool composition between hamsters and humans (Bravo et al, 1994). 
MATERIALS AND METHODS 
Chemicals and Diets 
The method of Chang et al. (1994) was modified to synthesize daidzein (Song et al, 
1998). Genistein was synthesized by a method of Chang et al. (1994). Glycitein was 
synthesized according to Lang'at-Thoruwa et al. (2003). The purity of isoflavones, 
determined by HPLC chromatogram peak area and Beckman Gold HPLC system peak purity 
software, was > 97%. All chemicals for isoflavone synthesis were purchased from Sigma-
Aldrich (St. Louis, MO). 
All dietary ingredients except rice flour were obtained from Harlan Teklad (Madison, 
WI). Rice flour was purchased from Bioserve (Frenchtown, NJ). Four treatments were fed: 
casein as control, daidzein, genistein, or glycitein (Table 1). The content of each isoflavones 
was -30% less than the total molar isoflavones content of isolated soy protein, 0.9 mmol/kg 
diet. The dose of each isoflavones was approximately 12.4 to 13.5 mg/kg body weight/day. 
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The casein diet did not contain isoflavones. The experimental diets contained -37% of 
energy as fat, 25% casein, and 0.1% cholesterol. Rice flour was used as a carbohydrate 
source because rice flour prevents "wet tail" disease, a form of chronic diarrhea with a high 
rate of mortality for hamsters (Terpstra et al. 1991). 
Animals 
The use of animals and the experimental protocol were approved by Iowa State 
Univeristy Animal Care Center Committee. Forty female Golden Syrian hamsters, 11-12 
weeks old, were purchased from Harlan Teklad (Madison, WI) and housed individually in 
temperature-controlled room (23 °C) with a 12-h light : dark cycle. Hamsters were randomly 
assigned to four treatments with the same average body weight in each group. Hamsters had 
free access to food and water during the 4-week experimental period. Body weights were 
measured weekly and food intakes were measured daily. At the end of the feeding period, 
diets were withdrawn from hamsters 16-18 hours before they were sacrificed under CO2. 
Blood was collected by cardiac puncture and centrifuged at 5000 x g for 15 min at 4°C to 
prepare plasma that was stored at -20°C until analysis. 
Plasma lipid analysis 
Plasma total cholesterol and HDL cholesterol concentration were measured with 
Sigma diagnostics kits (St. Louis, MO). Plasma triglycerides were measured with Thermo 
Trace kits (Louisville, CO). Non-HDL cholesterol was calculated by subtraction of HDL 
cholesterol from total cholesterol and represented LDL+IDL+VLDL cholesterol. 
Analysis of urinary excretion of isoflavones 
Hamsters were put in metabolic cages for 24 hours to collect urine during the last 2 or 
3 days of the feeding period. Urine sample (5 mL) was mixed with 5 mL sodium acetate 
buffer (0.2 M, pH5.5), 50 pL of P-glucuronidase/sulfatase (H2 type, Sigma-Aldrich, St. 
Louis, MO), and 50 pL of 2,4,4-trihydroxydeoxybenzoin (THE as an internal standard, 2 
mg/ml) in a tube. After incubation for 20 hours at 37°C on a shaker, 9 mL of sodium 
phosphate buffer (10 mM, pH 7.0) was added and the solution was passed through an 
Extrelut QE column (EM Science, Gibbstown, NJ). The column was washed 2 times with 18 
mL ethyl acetate (HPLC grade) and one time with 10 mL ethyl acetate (HPLC grade). The 
effluent was collected in a round-bottom flask, and dried in a rotary evaporator (Buchler 
Instrument, Fortlee, NJ). The dried residues were dissolved in 9.8 mL 20% ethanol and 
acidified by 200 (iL of 1 N HC1. Five mL of ethanol-dissolved residue was slowly applied to 
a pre-conditioned Sep-Pak cartridge (CI8, Waters Crop. Milford, MA). The cartridge was 
washed 2 times with 2 mL distilled water to remove the water soluble impurities and the 
eluent recovered in 2 mL of 80% methanol. The extract was vortexed and filtered through a 
0.45 mm PTFE filter (Alltech Associates Inc., Deerfield, IL) prior to HPLC analysis. 
The HPLC analysis was carried out on a Hewlett Packard 1050 Series HPLC system. 
This system consisted of a photodiode array detector (PDA), a quadruplicate pumping 
system, an autosampler and an HP Vectra 486/66 personal computer with Chem Station 3D 
software (Hewlett Packard Company, Scientific Instruments Division, Palo Alto, CA). 
Daidzein, genistein, glycitein, and THE were detected and quantified on a YMC-pack ODS-
AM C18 reverse phase column (5 jxm pore size, 25 cm x 4.6 mm, YMC, Inc., Wilmington, 
NC). Elution was carried out at a flow rate of 1 mL/min at ambient temperature with the 
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following solvent system. 0.1% acetic acid in Milli-Q H2O (Millipore Co, Bedford, MA) 
(solvent A) and methanol (solvent B). After injection of 20 jiL sample, solvent B was 
increased from 30% to 50% in 45 min, then held at 50% for 10 min, and decreased to 30% in 
10 minutes. Analytes were monitored with PDA from 190 to 350 nm. Ultraviolet absorbance 
spectra were recorded and area responses were integrated by Chem Station 3D Software to 
identify isoflavones. Recovery based on the THE internal standard was 84%, and recovery-
adjusted urinary excretion of each isoflavone concentration as a percentage of ingested dose 
was reported. 
Statistical analysis 
All statistical analyses were conducted with the Statistical Analysis System (SAS, 
Release 8.2, SAS Institute Inc., Cary, NC). Values were expressed as means ± SD. The 
results were analyzed by one-way analysis of variance (ANOVA). Differences between 
treatments were determined by least significant difference test. An a of 0.05 was used to 
determine statistically significant differences. 
RESULTS 
Body weights and food intakes 
The powdered diets were well accepted by hamsters throughout the experiment. 
There were no daily food intake differences among dietary treatment groups (Table 2). 
Hamsters in all groups had similar initial mean body weights. No significant differences were 
found among the different groups for the final mean body weight (Table 2). 
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Effects of isoflavones on plasma lipid concentrations 
Hamsters fed glycitein had significantly lower total cholesterol and non-HDL 
cholesterol concentrations (P < 0.05) compared with those fed casein (Table 3). Plasma HDL 
cholesterol and triglyceride concentrations were not significantly affected by dietary 
treatments (Table 3). 
Percentage of urinary recovery of each isoflavone 
The percentage of urinary recovery of ingested dose of each isoflavone was glycitein 
(32.2+29.7%)> daidzein (4.6+1.8%) > genistein (2.2+1.7%) (Figure 3). Hamsters fed 
glycitein had significantly greater urinary isoflavone recovery (P < 0.05) compared with 
those fed daidzein or genistein (Figure 3). Seemingly, glycitein was more available in the 
body compared with the other two dietary isoflavones. 
DISCUSSION 
The present study was designed to determine if daidzein, genistein, or glycitein 
lowered plasma cholesterol in female Golden Syrian hamsters fed these compounds. Pure 
synthetic isoflavones were added to a casein-based diet to avoid the possible confounding 
effects of other alcohol extractable components of soy protein such as soyasaponins. 
Hamsters fed pure synthetic glycitein had lower plasma total and non-HDL 
cholesterol concentrations by 15% and 24%, respectively, compared with those fed casein. 
Daidzein or genistein showed intermediate cholesterol-lowering effects compared with either 
casein or glycitein (Table 3). These results confirmed our hypothesis that soy isoflavones 
play a role in lowering plasma cholesterol concentrations, separate from soy protein. 
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In a previous study (Song et al, 2003), hamsters fed pure synthetic daidzein at 1.3 
mmol/kg diet (or -16 mg/kg body weight/d) for 10 weeks had significantly lower plasma 
total and non-HDL cholesterol concentrations by 22-24% and 30-38% compared with those 
fed casein. In the present study, the content of daidzein was -30% less than Song's study (1.3 
mmol daidzein/kg diet), 0.9 mmol/kg diet (or 12 mg to 13 mg/kg body weight/d). After a 4 
wk feeding period, daidzein lowered plasma total and non-HDL cholesterol by 7% and 14%, 
respectively, compared with casein. Perhaps if a longer experimental period was conducted, a 
significant reduction of plasma total and non-HDL cholesterol might be observed with 
daidzein as well. Demonty et al. (2002) reported that a mixture of pure synthetic daidzein 
and genistein at 1.4 mmol/kg diet (or -23 mg/kg body weight/d) significantly lowered 
plasma triglycerides by 26% compared with casein in Sprague-Dawley rats. Ovariectomized 
rats fed isolated pure isoflavone glycosides daidzin (25 or 50 mg/kg body weight/d) or 
genistin (50 mg/kg body weight/d) orally using a stomach tube resulted in significantly lower 
plasma total cholesterol (by 23-44%) and triglyceride (by 24-46%) concentrations compared 
with casein (Uesugi et al, 2001). Based on the results from these studies, soy isoflavones 
have the ability to lower plasma lipid concentrations, separate from soy protein in rodents. 
Potential mechanisms of soy isoflavones in lowering plasma cholesterol levels are not 
clear. Soy isoflavones have similar structure to natural estrogens and can bind estrogen 
receptors (ER-a and -P), especially ER-(3. The loss of estrogen increased plasma 
concentrations of total cholesterol, LDL cholesterol, and triglycerides and decreased HDL 
cholesterol in women (Jensen, 1992; Gaspard et al, 1995). Jensen (1992) investigated the 
changes of plasma lipid concentrations after natural menopause in 170 premenopausal 
women. After menopause, women significantly increased plasma total (by 6%) and LDL 
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cholesterol (by 8%) and decreased HDL cholesterol (by 7%) level. It may be possible that 
soy isoflavones may affect plasma lipid concentrations through their estrogenic activity. 
Angelin et al. (1992) obtained liver biopsies from male patients with either estrogen or non-
estrogen treatment (control) and examined hepatic cholesterol metabolism. Hepatic 12"I-LDL 
binding activity (reflecting the expression of the LDL receptor) was increased in the 
estrogen-treated men compared with control. Kirk et al. (1998) reported that soy protein 
isolate containing isoflavones at 1.33 mmol/kg diet lowered plasma LDL cholesterol by 30% 
in C57BL/6 mice compared with soy protein lacking isoflavones. However, no cholesterol-
lowering effect by soy protein was observed in LDL receptor-deficient mice. These findings 
suggest that soy isoflavones may lower LDL cholesterol concentration through increased 
gene expression and activity of hepatic LDL receptor. Decreased non-HDL cholesterol levels 
observed in the present study may be explained by this possible mechanism. The potential 
mechanisms of isoflavones to reduce plasma lipid concentrations should be further 
investigated. 
In this study, there were no significant differences in plasma HDL cholesterol and 
triglyceride concentrations among different dietary treatments. These results were consistent 
with other studies (Balmir, et al, 1996; Ni et al, 1999). Balmir et al. (1996) reported that 
plasma HDL cholesterol and triglyceride concentrations were not significantly affected by 
dietary treatments (casein, casein with added alcohol extract containing approximately 0.3 
mmol total isoflavones/kg diet, casein with twice the level of extract providing 
approximately 0.6 mmol total isoflavones/kg diet, isolated soy protein (ISP), and ISP with 
alcohol extract) in hamsters. Female hamsters fed daidzein had no difference in plasma HDL 
cholesterol compared with casein (Song et al, 2003). 
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The percentage of urinary recovery of ingested doses of each isoflavone was greater 
in hamsters fed glycitein than in those fed the other two isoflavones (Figure 1 ). The 
percentage of urinary recovery of each isoflavone was glycitein > daidzein > genistein in this 
study. These results were similar to that of a previous study (unpublished data) in our 
laboratory that urinary isoflavone recovery was glycitein > daidzein > genistein in hamsters 
fed Novasoy containing 1.2 mmol or 1.8 mmol total isoflavones/kg diet. A different pattern 
of urinary recovery in human was reported by Zhang et al. (1999). The urinary recoveries in 
humans of daidzein, glycitein, and genistein were approximately 52%, 47%, 37%, 
respectively. The results suggest some differences between humans and hamsters probably 
due to differences between the species in metabolism and degradation of each isoflavone by 
intestinal microbes. In a previous study by Zheng et al. (2003), women who showed low 
fecal genistein disappearance rate and faster gut transit time had greater genistein 
bioavailability, as reflected in urinary recovery of genistein compared with women who had 
high genistein disappearance rate and long gut transit time. When seven subjects consumed 
isoflavones from soymilk, two of the subjects showed greater urinary recovery of ingested 
doses of isoflavones compared with other subjects (Xu et al, 1995). Hendrich et al. (1998) 
showed three different isoflavone disappearance phenotypes in humans and a negative 
correlation between plasma isoflavone concentrations and fecal isoflavone disappearance rate 
constant in 8 young adult men. These findings suggested that individual variability in 
metabolic response to isoflavones may be due to differences in the relative ability of gut 
microorganisms to degrade isoflavones, perhaps accounting for differences among species 
and isoflavones in apparent isoflavone absorption. 
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In conclusion, this study demonstrated glycitein's ability to lower plasma lipid 
concentrations. In female hamsters, glycitein's greater cholesterol-lowering effect is probably 
due to greater bioavailability, as reflected in urinary recovery of glycitein compared with the 
other purified isoflavones. 
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Table 1. Composition of experimental diets. 
Ingredient Casein Daidzein 
g/kg 
Genistein Glycitein 
Casein1 250 0 0 250 
Isoflavones 0 0.23 0.24 0.25 
Coconut oil 100 100 100 100 
Safflower oil 20 20 20 20 
Soybean oil 40 40 40 40 
Cellulose 75 75 75 75 
Wheat bran 75 75 75 75 
Choline chloride 3 3 3 3 
Vitamin mix2 10 10 10 10 
Mineral mix3 35 35 35 35 
Potassium bicarbonate 20 20 20 20 
Cholesterol 1 1 1 1 
Rice flour4 371 370.77 370.76 370.75 
Vitamin-free casein (Harlan/Teklad, Madison, WI) 
^Vitamin mixture #400160 (Harlan/Teklad, Madison, WI) 
^Mineral mixture #170910 (Harlan/Teklad, Madison, WI) 
4Rice flour (Bioserve, Frenchtown, NJ). 
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Table 2. Body weight change and food intake of hamsters fed casein or casein-based diets 
with each soy isoflavone1 
Treatment Food Intake Initial body weight Final body weight 
g/d g g 
Casein 7.5 ±1.2 111 ±10 126±9 
Daidzein 7.7±1.8 111 ±10 126±11 
Genistein 7.4 ±1.6 112 ±11 128 ±13 
Glycitein 7.3 ± 1.5 111 ±11 127 ± 13 
'Values represent means ± SD, n-10. 
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Table 3. Plasma cholesterol levels in hamsters fed casein diets containing daidzein, 
genistein, or glycitein1'2 
Treatment Total 
cholesterol 
mmol/L 
HDL 
cholesterol 
mmol/L 
Non-HDL3 
cholesterol 
mmol/L 
Total cholesterol 
/HDL cholesterol 
Triglyceride 
mmol/L 
Casein 6.33±L32a 3.75+0.53 2.58±0.81a 1.69±0.24a 2.67±0.24 
Daidzein 5.87±0.99^ 3.66+0.58 2.22±0.75ab 1.61±0.26ab 2.22+0.57 
Genistein 5.61±0.87ab 3.43+0.64 2.19+0.53ab 1.64+0.14ab 2.40+0.68 
Glycitein 5.34±0.61b 3.38±0.86 1.95+0.37b 1.58±0.19b 2.29+0.75 
'Values represent means ± SD, n=10; 
2Within a column, means with different superscripts are different (P < 0.05); 
"Represents the VLDL+IDL+LDL fractions (by difference: Total - HDL). 
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Figure 1. Percentage of urinary isoflavone recovery is a percentage of daily ingested 
dose in hamsters fed daidzein, genistein, or glycitein diets (P < 0.05). Data are reported 
as mean + SD, significant difference is noted by an asterisk. 
Urinary recovery (% of 24-h ingested dose) 
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GROUP B SOYASAPONINS LOWER PLASMA CHOLESTEROL AND 
INCREASE FECAL BILE ACIDS IN FEMALE GOLDEN SYRIAN 
HAMSTERS 
A paper to be submitted to Experimental Biology and Medicine 
Sun-Ok Lee, Andrean L Simons, Patricia A Murphy, and Suzanne Hendrich 
ABSTRACT 
A study was conducted in hamsters to determine if group B soyasaponins affect 
plasma lipid concentrations by increasing excretion of fecal bile acids and neutral sterols, to 
investigate the relationship between group B soyasaponin metabolite and plasma lipid levels, 
and to identify group B soyasaponin metabolites. Twenty female Golden Syrian hamsters, 
11-12 week old, 85-125 g, were randomly assigned to one of two dietary treatments fed for 4 
weeks. The content of group B soyasaponins was 2.2 mmol/kg diet and no isoflavones were 
detected in the group B soyasaponin diet. Hamsters fed group B soyasaponins had 
significantly lower plasma total cholesterol (by 20%), non-HDL cholesterol (by 33%), and 
triglyceride (by 18%) concentrations compared with those fed casein (P < 0.05). The ratio of 
total to HDL cholesterol was significantly lower in group B soyasaponins than casein (P < 
0.05). The excretion of fecal bile acids and neutral steroids were significantly greater in the 
soyasaponin group compared with the casein group (P < 0.05). Thus, group B soyasaponins 
lowered plasma total and non-HDL cholesterol levels by a mechanism involving greater 
excretion of fecal bile acids and neutral steroids compared with casein. Hamsters fed group B 
soyasaponins sorted into two fecal soyasaponins metabolite excretion phenotypes: high (n=3) 
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and low excreters (n=7). When low and high producers of a putative soyasaponin metabolite 
were compared for plasma cholesterol status, the high producers showed significantly lower 
total cholesterol/HDL cholesterol ratio compared with the low producers (1.38 ± 0.7 v. 1.59 
± 0.13), P < 0.03. Greater production of group B soyasaponin metabolite in hamsters was 
associated with better plasma cholesterol status, suggesting that gut microbial variation in 
soyasaponin metabolism may influence the health effects of group B soyasaponins. 
Keywords: group B soyasaponin, soyasaponin metabolite 
INTRODUCTION 
Soyasaponins are one of the major class of phytochemicals associated with soy 
protein. The primary saponins in soybeans are group A and B soyasaponins on the basis of 
their aglycone parts, soyasapogenols A and B (Gurfinkel et al., 2002; Rupasinghe et al., 
2003). The content of group B soyasaponins in whole soybean seeds is about 60-75% by 
weight of total soyasaponins (Gu et al., 2002; Ireland et al., 1986). Soybeans, isolated soy 
protein, and soy products provide soyasaponins approximately 1.4 to 5.9 nmol/g, 9.5 to 10.6 
^mol/g, and 1.5 to 4.5 pmol/g dry weight basis, respectively (Gu et al., 2002; Hu et al., 2002; 
Tsukamoto et al., 1995). 
Soyasaponins have been suggested as a factor capable of lowering plasma cholesterol 
concentrations (Oakenfull et al., 1984; Potter et al., 1995; Ueda et al., 1996; Fukui et al., 
2002). Plasma total cholesterol was significantly decreased in male Sprague-Dawley rats fed 
soy protein isolate, either intact or depleted of isoflavones but containing 49% of the amount 
of saponins present in the soy protein isolated-based diet compared with those fed casein 
(Fukui et al., 2002). Rats fed a 1% cholesterol diet with 1% purified soyasaponins had 
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significantly lowered plasma and hepatic total cholesterol levels compared with those fed the 
1% cholesterol diet (Oakenfull et al., 1984). 
The potential mechanisms responsible for the hypocholesterolemic effects of 
soyasaponins or synthetic saponins have been investigated (Oakenfull et al., 1984; Oakenfull 
and Sidhu, 1990; Morehouse et al., 1999; Oakenfull, 2001). Synthetic saponins, pamaqueside 
and tiqueside, significantly decreased intestinal absorption of cholesterol compared with a 
control diet (Morehouse et al., 1999). Oakenfull et al. (1984) found that 1% soyasaponins 
significantly increased fecal bile acid and neutral sterol excretion compared with a control 
diet without soyasaponin. Studies have yielded evidence that cholesterol-lowering effects of 
saponins may be mediated by decreased intestinal absorption of cholesterol or enhanced fecal 
excretion of bile acids or neutral sterols. 
Little is known about the metabolism and bioavailability of soyasaponins (Gestetner 
et al., 1968; Gurfinkel and Rao, 2003; Hu et al., in press, a and b). In an in vitro fermentation 
system, soybean saponins were hydrolyzed to soyasapogenols (aglycone saponins), partially 
hydrolyzed forms, and sugars by colonic microflora (Gurfinkel and Rao, 2003; Hu et al., in 
press, a). In vivo, neither soyasaponins nor soyasapogenols were detected in the blood of rats, 
mice, and chicks (Gestetner et al., 1968) and in human urine (Hu et al., in press, b). 
The present study was designed to investigate whether group B soyasaponins affect 
plasma lipid concentrations by increasing excretion of fecal bile acids and neutral sterols, to 
investigate the relationship between group B soyasaponin metabolite and plasma lipid levels, 
and to identify group B soyasaponin metabolites in female hamsters. To avoid the 
confounding effects of other alcohol-extractable components in soy, crude group B 
soyasaponins were fed in this study. 
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MATERIALS AND METHODS 
Diets 
Crude group B soyasaponins were generously donated by Dr. Mark Berhow (United 
States Department of Agriculture, National Center for Utilization of Agricultural Products, 
Peoria, EL). The soyasaponin fractions of crude group B soyasaponins were analyzed by 
HPLC (Hu et al., 2002). 
All dietary ingredients except rice flour were obtained from Harlan Teklad (Madison, 
WI). Rice flour was purchased from Bioserve (Frenchtown, NJ). Two treatments were fed: 
casein as control or group B soyasaponins (Table 1). The amount of group B soyasaponins 
fed in this study (Table 2) was similar to the amount of soyasaponins in a diet based on 25% 
isolated soy protein, 2.2 mmol/kg diet. The dose of group B soyasaponins was approximately 
128 mg/kg body weight/d. No isoflavones were detected in group B soyasaponin diet. The 
experimental diets contained -37% of energy as fat, 25% casein and 0.1% cholesterol. Rice 
flour was used as a carbohydrate source to replace cornstarch in the standard rodent diet 
because rice flour prevents a chronic diarrhea that cause a high rate of mortality for hamsters 
(Terpstra et al. 1991). 
Animals 
The use of animals and the experimental protocol were approved by Iowa State 
University Animal Care Center Committee. Twenty female golden Syrian hamsters, 11-12 
week old, 85-125 g, were purchased from Harlan Teklad (Madison, WI) and housed 
individually in temperature-controlled room (23°C) with a 12 hours light : dark cycle. 
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Hamsters were randomly assigned to two treatments with the same average body weight in 
each group. Hamsters had free access to food and water during the 4-week experimental 
period. Body weights were measured weekly and food intakes were measured daily. At the 
end of the feeding period, diets were withdrawn from hamsters 16-18 hours before they were 
sacrificed under C02. Blood was collected by cardiac puncture and centrifuged at 5000 x g 
for 15 min at 4°C to prepare plasma that was stored at -20°C until analysis. 
Plasma lipid analysis 
Plasma total cholesterol and HDL cholesterol concentration were measured with 
Sigma diagnostics kits (St. Louis, MO). Plasma triglycerides were measured with Thermo 
Trace kits (Louisville, CO). Non-HDL cholesterol was calculated by subtraction of HDL 
cholesterol from total cholesterol and represented LDL+EDL+VLDL cholesterol. 
Analysis of fecal bile acids and neutral sterols 
Fecal samples were collected over 24-hour intervals for the last 2 or 3 days of the 
feeding period. Quantitation of bile acids and neutral sterols in feces was measured by gas-
liquid chromatography according to the method of Batta et al. (2002). Two hundred 
microliters of n-butanol which contained cholic acid and 5a-cholestane (internal standards) 
and 50 jjL of concentrated hydrochloric acid were added to 15 mg of freeze-dried fecal 
samples and to the standards (10 and 20 |ig of each bile acid and neutral sterol). The mixture 
was heated at 60°C for 4 hours and then solvents evaporated at 60°C under N%. The butyl 
esterified bile acids, the neutral sterol standards, and fecal samples were reacted with 100 |±L 
of Sil-prep (trimethyl silylation reagent, Alltech Associates Inc., Deerfield, IL) for 30 
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minutes at 55°C. Solvents were evaporated at 55°C under N2. Trimethyl silyl ether derivative 
of fecal samples and standards were resuspended in 200 joL hexane, centrifuged to separate 
the fecal debris, and injected 2 onto the gas-chromatography column. 
Analysis was performed using a Varian Chrompak CP-Sil 5 CB Low Bleed/MS fused 
silica capillary column, 25 M x 0.25 mm ID x 0.25 mm film thickness (Supelco Park, 
Bellefonte, PA) installed in a Hewlett Packard 6890 gas chromatograph equipped with a 
flame ionization detector and autosampler. Carrier gas was helium at a flow rate of 1.5 
mL/min. Injector temperature was 260°C and detector temperature was 290°C. Peaks were 
identified by comparing retention times with those of authentic bile acids (hyodeoxycholic 
acid, deoxycholic acid, hyocholic acid, cholic acid, chenodeoxycholic acid, ursodeoxycholic 
acid, ursocholic acid, and lithocholic acid) or neutral sterol standards (coprostanol, 
campesterol, stigmasterol, stigmastanol, cholestanone, cholesterol, cholestenone, cholestane, 
^-sitosterol, lanosterol, and lathosterol) (Steraloids Inc., Newport, RI). The weight 
percentage of each bile acid and neutral sterol was determined by integration of the peak 
areas. 
Extraction of fecal samples 
A method of Hu et al. (2004a) was used to extract fecal samples. Hamsters were put 
in metabolic cages for 24 hours to collect fecal samples. One gram of ground fecal sample 
was weighed and extracted with 50 mL of 70 % ethanol at room temperature for 2 hours. The 
extract was filtered through Whatman filter paper. Then the filtrate was collected in a round-
bottom flask, and dried in a rotary evaporator (Buchler Instrument, Fort Lee, NJ). The dried 
residues were dissolved in 5 mL of 20% methanol and slowly applied onto a pre-conditioned 
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Sep-Pak cartridge (Cl8, Waters Crop. Milford, MA). The cartridge was washed with 5 mL of 
distilled water to remove the water soluble impurities followed by 5 mL of 30% methanol. 
The eluent was recovered in 1 mL of HPLC grade methanol. The extract was vortexed and 
filtered through a 0.45 mm PTFE filter (Alltech Associates Inc., Deerfield, IL) prior to HPLC 
analysis. 
Group B soyasaponin metabolite was determined by HPLC system as previously 
reported (Hu et al., 2002). Elution was carried out at a flow rate of 1 mL/min with the 
following solvent system: 0.05% trifluoroacetic acid in Milli-Q water (Millipore Co., 
Bedford, MA) (solvent A) and acetonitrile (solvent B). After injection of 50 jjL sample, 
solvent B was increased from 73% to 100% linearly in 35 min; then, solvent was recycled 
back to 73% in 4 minutes. The column temperature was 30°C. Ultraviolet absorbance 
monitored analytes from 190 to 350 nm using a photodiode array detector. 
Preparation of soyasapogenol B and identification of soyasaponin metabolite 
Soyasapogenol B was prepared according to Hu et al. (2004a) and uses as a standard 
to compare with soyasaponin metabolite. The chemical structure of soyasaponin metabolite 
was identified by *H, 13C-NMR, electrospray ionized (ESI) mass spectroscopy, and infrared 
absorbance analyses. H NMR and 13C Attached Proton Test NMR spectra were acquired on 
a Varian VXR-300 spectrometer (Varian Inc., Palo Alto, CA). A Finnigan TSQ 700 triple 
quadrupole mass spectrometer (Finnigan MAT, San Jose, CA) equipped with a Finnigan ESI 
interface was used in the positive QIMS mode. The sample was dissolved in methanol-^ or 
cholorofbrm-dé (Cambridge Isotope Laboratories, Inc., Andover, MA). The 'H and 13C-NMR 
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spectra data of soyasapogenol B were in good agreement with those reported by Kudou et al. 
(1993) and Hu et al. (2004a). 
Statistical analysis 
Statistical analyses were conducted with the Statistical Analysis System (SAS, 
Release 8.2, SAS Institute Inc., Cary, NC). Values were expressed as means ± SD. A cluster 
analysis was performed to classify fecal soyasaponin metabolite excretion phenotypes. The 
results were analyzed by one-way analysis of variance (ANOVA). Differences between 
treatments were determined by least significant difference test. An a of 0.05 was used to 
determine statistically significant differences. 
RESULTS 
Hamster body weights and food intakes 
The powdered diets were well accepted by hamsters throughout the experiment. Daily 
food intakes did not differ between casein and group B soyasaponin treatments (Table 3). 
Hamsters in both groups had similar initial mean body weight. There were no final weight 
differences between casein and group B soyasaponin groups (Table 3). 
Effects of group B soyasaponins on plasma lipid concentrations 
Total cholesterol, non-HDL cholesterol, triglyceride concentrations and total 
cholesterol/HDL cholesterol ratio were significantly less in hamsters fed group B 
soyasaponins (P < 0.05) compared with casein-fed hamsters (Table 4). There were no 
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differences in HDL cholesterol concentrations between groups fed casein or group B 
soyasaponin groups (Table 4). 
Fecal bile acids and neutral sterols 
There were significant effects of dietary treatment on both bile acid and neutral sterol 
outputs (Figure 1). Mean value of fecal bile acid and neutral sterol outputs was significantly 
greater in hamsters fed group B soyasaponins (P < 0.05) compared with those fed casein 
(Figure 1). 
Fecal soyasaponin metabolite excretion 
The retention time of a putative soyasaponin metabolite was -22 min on HPLC 
system (Figure 2B) whereas the retention time of soyasapogenol B was -15 min (Figure 2A). 
According to a cluster analysis, hamsters fed group B soyasaponins sorted into two fecal 
soyasaponin metabolite excretion phenotypes: high (n=3) and low (n=7) excreters (Figure 3). 
Effects of group B soyasaponin metabolite on plasma lipid concentrations 
There were no significant differences in plasma total, HDL cholesterol, non-HDL 
cholesterol, and triglyceride concentrations between high producer and low producer of 
soyasaponin metabolite (Table 5). The high producers of soyasaponin metabolite showed 
improved plasma cholesterol levels (the ratio of total/HDL cholesterol) compared with the 
low producers of the soyasaponin metabolite (P < 0.03) (Table 5). 
Identification of soyasaponin metabolite 
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'H-NMR (400 MHz) spectra of soyasaponin metabolite showed signals at ô 5.53 (m, 
4H), 2.96 (t, J = 6.0 Hz, 2H), 2.46 (t,J= 7.6 Hz, 3H), 2.25 (d, J= 6.4 Hz, 4H), 1.78 (s, 3H), 
1.50 (d, J= 15.2 Hz, 24H), and 1.06 (m, 6H). The 13C-NMR (100 MHz) spectrum of 
soyasaponin metabolite exhibited carbon signals at 177.9, 131.1, 131.0, 129.3, 129.2, 37.9, 
35.9, 35.1, 32.8, 31.3, 31.0, 30.9, 30.8, 30.7, 30.5, 30.4, 28.3, 26.7, and 26.3 ppm. The 13C-
NMR spectrum at 131.1, 130.0, 129.3, 129.2, and 177.9 ppm indicated the presence of two 
double bonds and one carbonyl stretching band. The positive mode ESI spectra of 
soyasapogenol B and soyasaponin metabolite were ion peak at m/z 332 [M+5CH.30H+2Na]2 
and m/z 393 [M-COOH]respectively. The carboxyl group of soyasaponin metabolite was 
confirmed with its infrared absorbance spectrum, absorbing in the region 1600-1800 cm"1. 
The molecular formula and weight of soyasaponin metabolite were estimated by elemental 
analysis, C30H46O2 and 438, respectively. The molecular weight is a value calculated based 
on the molecular formula. The putative structure of this soyasaponin metabolite was shown 
in Figure 4. 
DISCUSSION 
The present data demonstrated that group B soyasaponins lowered plasma total, non-
HDL cholesterol, triglyceride concentrations and the ratio of total to HDL cholesterol in 
female hamsters (Table 4). Greater fecal excretion of bile acids and neutral sterols were 
observed in hamsters fed soyasaponins compared with those fed casein (Figure 1). The 
results were similar to that of Oakenfull et al. (1984) that 1% cholesterol diet plus 1% 
purified soyasaponins significantly lowered plasma (26%) and hepatic (33%) total 
cholesterol by increasing excretion of fecal bile acids and neutral sterols in rats compared 
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with 1% cholesterol diet. In the present study, significant reduction of non-HDL cholesterol 
and triglyceride levels in hamsters fed soyasaponins may be a consequence of decreased 
hepatic cholesterol reserve as a result of inhibiting intestinal absorption of cholesterol or 
increasing fecal excretion of bile acids and neutral sterols. Taken together, these data 
suggested that cholesterol-lowering effect of group B soyasaponins was mediated by 
increased fecal outputs of bile acids and neutral sterols and inhibition of intestinal absorption 
of cholesterol and bile acids. 
Fewer studies have been reported about the metabolic fate of soyasaponins 
(Gestntetner et al., 1968, Gurfinkel and Rao, 2003; Hu et al., in press, a and b). In vitro 
fermentation, Gurfinkel and Rao (2003) found that group A and B soyasaponins were 
hydrolyzed by colonic microflora to produce soyasapogenol A and soyasapogenol B, 
respectively. Hu et al. (2004a) reported that two gut microbial metabolites of soyasaponin I, 
soyasaponin III and soyasapogenol B, were identified when human feces were incubated in a 
brain-heart-infusion media with soyasaponin I (10 pmol /g feces) for 48 hours at 37°C. In 
vivo studies, Gestetner et al. (1968) found that soyasaponins or soyasapogenols were not 
detected in the blood of rats, mice, and chicks. Only soyasapogenol B (8.4% of ingested 
soyasaponin dose recovered in feces) was detected in human feces after a single dose of soy 
extract containing 434 [imol of group B soyasapogenins. Neither soyasapogenol B nor other 
soyasaponins were found in human urine samples (Hu et al., in press, b). These findings 
suggested that soyasaponins might not be absorbed from the digestive tract, but all rather 
metabolized by intestinal microorganisms, and excreted in the feces. 
In the present study, a new metabolite of group B soyasaponins was detected in 
hamster feces after a 4-week feeding period, but neither soyasaponins nor soyasapogenol B 
I l l  
were found (Figure 2). These results suggested that soyasaponins were further metabolized or 
degraded by intestinal microflora. All hamsters fed group B soyasaponins produced 
soyasaponin metabolite. By cluster analysis, we found that there were two fecal soyasaponin 
metabolite excretion phenotypes: high and low. When low and high producers of a putative 
soyasaponin metabolite were compared for plasma cholesterol status, the high producers of 
soyasaponin metabolite showed significantly lower total/HDL cholesterol ratio (p < 0.03) 
(Table 5). Nonsignificant reduction in plasma non-HDL cholesterol (p < 0.07) was observed 
in the high producers of soyasaponin metabolite. Perhaps if a larger number of animals were 
analyzed, the presence of this saponins metabolite might be associated with a significant 
improvement in plasma non-HDL cholesterol concentration. 
In conclusion, group B soyasaponins lowered plasma cholesterol levels by a 
mechanism involving greater excretion of fecal bile acids and neutral steroids compared with 
casein. Greater production of soyasaponin metabolite in hamsters was associated with better 
plasma cholesterol status. It is difficult to understand or assess the biological activity and 
health benefits of soyasaponins because of the lack of information about the metabolic fate of 
soyasaponins in animals and humans. Therefore, further study will be needed to investigate 
the role of group B soyasaponin metabolite on plasma cholesterol concentrations. 
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Table 1. Composition of experimental diets. 
Ingredient Casein 
g/kg 
Soyasaponins 
Casein1 250 250 
Soyasaponins 0 2.4 
Coconut oil 100 100 
Safflower oil 20 20 
Soybean oil 40 40 
Cellulose 75 75 
Wheat bran 75 75 
Choline chloride 3 3 
Vitamin mix2 10 10 
Mineral mix3 35 35 
Potassium bicarbonate 20 20 
Cholesterol 1 1 
Rice flour4 371 368.5 
Vitamin-free casein (Harlan/Teklad, Madison, WI) 
2Vitamin mixture #400160 (Harlan/Teklad, Madison, WI) 
"Mineral mixture #170910 (Harlan/Teklad, Madison, WI) 
4Rice flour (Bioserve, Frenchtown, NJ). 
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Table 2. Dietary soyasaponin contents (mg/g diet) 
Soyasaponin 
V 
Soyasaponin 
I 
Soyasaponin 
II 
Soyasaponin 
ag 
Soyasaponin 
Pg 
Soyasaponin 
pa 
— 
1.36 1.04 0 0 0 
No isoflavones were detected. 
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Table 3. Body weight change and food intake of hamsters fed casein or casein-based diets 
with each soy isoflavone1 
Treatment Food Intake Initial body weight Final body w eight 
g/d g g 
Casein 7.5 ±1.2 111 ± 10 126 ± 9 
Soyasaponin 7.2 ±1.5 112 ± 11 128 ± 14 
'Values represent means ± SD, n=10. 
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Table 4. Plasma cholesterol levels in hamsters fed casein or group B soyasaponin diets1'2 
Treatment Total HDL 
cholesterol cholesterol 
mmol/L mmol/L 
Casein 6.33±1.32a 3.75±0.53 
Soyasaponin 5.14±0.79b 3.43±0.69 
Non-HDL3 Total cholesterol Triglyceride 
cholesterol /HDL cholesterol 
mmol/L mmol/L 
2.58±0.81a 1.69±0.24a 2.67±0.24a 
1.71±0.49b 1.50±0.14b 2.18±0.57b 
'Values represent means ± SD, n=10; 
"Within a column, means with different superscripts are different (P < 0.05); 
^Represents the VLDL+IDL+LDL fractions (by difference: Total - HDL) 
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Table 5. Plasma lipid status of high or low producers of soyasaponin metabolite1"2 
Total HDL Non-HDL Total cholesterol Triglyceride 
cholesterol cholesterol cholesterol /HDL cholesterol 
mmol/L mmol/L mmol/L mmol/L 
High producers 4.68±0.18 3.39±0.18 1.284=0.18 1.38+0.07" 1.73±0.49 
(n=3) 
Low producers 5.35±0.88 3.37±0.47 1.98±0.55 1.59±0.13a 2.38±0.71 
(n=7) 
'Values represent means ± SD; 
2Within a column, means with different superscripts are different (P < 0.03); 
"Represents the VLDL+IDL+LDL fractions (by difference: Total - HDL) 
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Figure 1. Fecal excretion of bile acids and neutral steroids per day. Data are reported as 
mean + SD. An asterisk indicates P < 0.05 vs casein. 
Figure 2. HPLC chromatograms. 
A: Chromatogram of soyasapogenol B 
B: Chromatogram of putative fecal group B soyasaponin metabolite 
Figure 3. Fecal soyasaponin metabolite excretion phenotypes. 
Figure 4. Putative structure of soyasaponin metabolite. 
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GENERAL CONCLUSIONS 
Soy protein and soy protein-associated components including isoflavones and 
soyasaponins have received attention regarding their possible role in lipid metabolism. Not 
many studies have investigated the hypocholesterolemic effect of the soy protein fraction, 
specifically P-conglycinin, in animals and humans. Most of the studies used an isolated soy 
protein extract rich in isoflavones and soyasaponins or an alcohol-washed isolated soy 
protein deficient in isoflavones and soyasaponins for investigating the cholesterol-lowering 
effects of isoflavones. Also, the content of soyasaponins was not well determined in other 
studies. Therefore, it is not clear which soy components are responsible for the cholesterol-
lowering effects. In order to clarify which components of soy protein reduce plasma lipid 
concentrations, it is necessary to exam the isoflavones or soyasaponins, separate from soy 
protein. 
In our first study, we found that (3-conglycinin with low levels of isoflavones and 
soyasaponins was ineffective at lowering plasma cholesterol over time in mildly 
hypercholesterolemic women. This study suggested that isoflavones and soyasaponins seem 
to be needed in companions for (3-conglycinin to exert a cholesterol lowering effect. To avoid 
the possible confounding effects of other alcohol extractable components of soy protein, such 
as soyasaponins, pure synthetic isoflavones were added to a casein-based diet. Glycitein's 
greater hypocholesterolemic effect due to greater bioavailability, as reflected in urinary 
recovery of glycitein compared with the other purified isoflavones. Further studies can be in 
the directions of investigating the potential mechanisms of each purified isoflavones to lower 
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plasma lipid concentrations, and examining the effects of different doses of each isoflavones 
in reducing plasma lipid levels (dose-response study). 
Not many of the biological activities associated with soyasaponins have been 
investigated because of the lack of availability of large quantities of purified soyasaponins 
and efficient methods for the detection and identification of soyasaponins and their 
metabolites. Our study used crude group B soyasaponins not containing isoflavones to avoid 
the possible confounding effects of other alcohol extractable components of soy protein. 
Group B soyasaponins lowered plasma lipid concentrations by increasing excretion of fecal 
bile acids and neutral sterols. Further studies will be needed to determine which soyasaponins 
fractions of soy, including soyasaponin otg, Pg, Pg, V, I, or II, have more cholesterol-
lowering effect. A new soyasaponin metabolite was detected in hamster's fecal sample after a 
4 week feeding period. The high producers of this metabolite showed improved plasma lipid 
status (the ratio of total/HDL cholesterol). It is difficult to understand or assess the biological 
activity and health benefits of soyasaponins because of the lack of information about the 
metabolic fate of soyasaponins in animals and humans. Therefore, further study will be 
needed to investigate the role of soyasaponin metabolite on plasma lipid concentrations. 
In summary, both soy isoflavones and soyasaponins in nutritionally relevant 
concentrations contribute to the cholesterol-lowering effects of soy foods and soy protein 
ingredients. 
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